

C t t

P

Continuity of Management

Board of Directors

Executive Directors

M. GUAN W (Chairman)

M. WANG L (Vice Chairman)

Non-Executive Directors

M. QIN H

M. LI C

Independent Non-Executive Directors

M. ZHONG W

M. LIU N

Audit Committee

M. ZHONG W (Chairman)

M. LIU N

M. LI C

Nominating Committee

M. LIU N (Chairman)

M. GUAN W

Remuneration Committee

M. ZHONG W

M. LIU N

Supervisory Board

M. GUAN W (Chairman)

M. ZHONG W

M. QIN H

Independent Supervisors

M. XU N (Chairman)

M. XU Y

M. XIE T

M. QIAN C

Executive Management

M. WANG J

M. WONG W (CFO)

Administrative Management

M. GUAN W

M. WONG W (CFO)

Legal Affairs

BDO C S L P C P A LLP

Legal Affairs Department

C C

Registered Office

PRC

S R

H R D

W, Z

PRC

CONTACT INFORMATION

Parent Company: Wenzhou Kangning Hospital Co., Ltd.

40/F, Daxue Road, Fuyuan District, Wenzhou

248 Qianjiang Road, Erqi District, Wenzhou

Wenzhou

China

Headquarters: Wenzhou Kangning Hospital Co., Ltd.

China Wenzhou Kangning Hospital Co., Ltd. S. 1712-1716, 17 F

S. 1712-1716, 17 F

H. 1712-1716, 17 F

183 Qianjiang Road, Erqi District, Wenzhou

Wenzhou

China

S. 1712-1716, 17 F

2120

China Wenzhou Kangning Hospital Co., Ltd. S. 1712-1716, 17 F

S. 1712-1716, 17 F

Headquarters: Wenzhou Kangning Hospital Co., Ltd.

Tel: (86) 577 8877 1689

Fax: (86) 577 8878 9117

E-mail: @

五、合并现金流量表

合并现金流量表

	2022 MB'000	2021 RMB'000 (人民币)	2020 RMB'000 (人民币)	2019 RMB'000	2018 RMB'000
经营活动产生的现金流量	1,484,903	1,297,430	989,012	860,692	745,972
投资活动产生的现金流量	15,605	95,691	83,509	55,523	106,910
筹资活动产生的现金流量	26,574	54,831	30,662	-17,295	-31,941
汇率变动对现金及现金等价物的影响	-10,969	40,860	52,847	38,228	74,969
现金及现金等价物净增加额	-24,221	44,036	64,961	57,289	80,596
期初现金及现金等价物余额	13,252	-3,176	-12,114	-19,061	-5,627

	2022 MB'000	2021 RMB'000 (人民币)	2020 RMB'000 (人民币)	2019 RMB'000	2018 RMB'000
购买商品、接受劳务支付的现金	2,637,787	2,377,955	2,161,262	2,117,352	1,840,724
支付给职工以及为职工支付的现金	1,311,885	1,097,676	946,349	855,843	635,451
支付的各项税费	1,325,903	1,280,279	1,214,913	1,261,509	1,205,273
支付其他与经营活动有关的现金	1,201,585	1,208,264	1,122,248	1,164,484	1,120,995
经营活动现金流出小计	124,318	72,015	92,665	97,025	84,278

注：报告期内，公司合并现金流量表各项目金额与母公司现金流量表各项目金额存在差异，主要系合并范围内子公司现金流量表各项目金额与母公司现金流量表各项目金额存在差异所致。

D
1,107
I
G
-
COVID-19

D
R
P
G
-
COVID-19

I
M
COVID-19

12,172
3,266

I 2022, G 14.4% 2021, RMB1,484.9 , RMB1,366.8 , 13.6% 2021. L G , G , 2021 29 2022 (). T 8,728 2021 9,688 2022. W , G , , G ,

I 2022, G - , G . T , - ,

T , L , G , K !

F B D , I ,

GUAN W

C

Z , PRC

A 28, 2023

O O 25, 16, C C C C P S C H

M t D , A y

[illegible]

O S 9, 2021, S C H C N H R A P (2021-2025), 100

O J 10, 2022, 21 N D R C (NDRC) N

H C P S P 14 F -Y P ,

I ,

, ,

,

.

O A 27, 2022, G O S C 14 F -Y P N H ,
 ,
 ,
 ,
 ,
 ,
 ,
 .

O D 14, 2022, C C C P C S C O
S P E D D (2022-2035), C S C O
C,
, -

M 2022 D 2022 A

B R

I 2022, C H C I . W , G , - , G ,

T G , 2022. D R P , G , W K H , G K H , Q K H , Y K H Y K H . I , G K H , Q K H Y K H , I , G , P Y H , C ,

Mit D. A. y.

COVID-19, G
G 1,107 , 12,172 . I 2022,
3.266 . I ,
G -
COVID-19 COVID-19

I 2022, G

B H

I 2022, G ' I.T. , G , J H , 31, 2022, 42 3 .O , G - + , ,

I 2022, G Z P C R C P M D
Z P B N C R C M D , -
N N S F C T G
I S T C B D P A , D D
T Z P
A , G NSSI (N -S
S -I A), L G P (D ADHD D T), L T ,
K P Z P ,

Management Discussion and Analysis

Financial Results

During the year, the Company's total revenue was RMB1,484.9 million, an increase of 14.4% compared with 2021. Among them, the revenue of the main business was RMB1,366.8 million, an increase of 13.6% compared with 2021. The revenue of the other business was RMB118.1 million, an increase of 23.9% (2021: 25.4%). The revenue of the main business was RMB352.9 million, an increase of 7.3% compared with 2021. The revenue of the other business was RMB-24.2 million, a decrease of 17.2% compared with 2021. The revenue of the main business was RMB41.1 million, an increase of 17.2% compared with 2021. The revenue of the other business was RMB227.2 million, an increase of 17.2% compared with 2021.

Revenue and Cost

During the year, the Company's total revenue was RMB1,484.9 million, an increase of 14.4% compared with 2021. Among them, the revenue of the main business was RMB1,366.8 million, an increase of 13.6% compared with 2021. The revenue of the other business was RMB118.1 million, an increase of 23.9% (2021: 25.4%). The revenue of the main business was RMB352.9 million, an increase of 7.3% compared with 2021. The revenue of the other business was RMB-24.2 million, a decrease of 17.2% compared with 2021. The revenue of the main business was RMB41.1 million, an increase of 17.2% compared with 2021. The revenue of the other business was RMB227.2 million, an increase of 17.2% compared with 2021.

For the year ended December 31,
2022
(in MB'000)

2021
(RMB'000)

F R P , G ' B R RMB1,425.0 , 15.9%
2021, . D R P , W
RMB43.5 , 2021. T G 2023. D R
P , RMB14.6 , RMB12.6 2021,

Management Discussion and Analysis

The Company's management discussion and analysis of the financial performance, financial position, and other financial information for the period from January 1, 2022, to December 31, 2022, is as follows:

	February 28, 2022 (MB'000)	December 31, 2021 (RMB'000)
Operating income		
Billing	1,119,887	962,408
Cost of sales	770,287	658,194
Gross profit	349,600	304,214
Operating expenses		
Billing	305,118	267,588
Cost of sales	269,828	238,918
Gross profit	35,290	28,670
Operating income, before tax	1,425,005	1,229,996
Cost of sales	1,040,115	897,112
Gross profit	384,890	332,884

During the reporting period, the Company's operating income, before tax, was RMB1,425.0 million, and the gross profit was RMB384.9 million.

Mit D. A. y.

D R P , B R RMB1,218.3 ,
15.6% 2021, : () G ,
13.0%, - Q K H , Y K
H , T K H , W N H , W C H , P C Y
H , Y Y H J S H ; () -
G , 2.4%. T B R B R
85.5% (2021: 85.7%).

D R P , B R RMB206.7 , 17.2% 2021, 30.9% 10.5%. T 14.5% (2021: 14.3%).

D R P , B R
16.4% 2021, 78.6% (2021: 78.2%)
B R ; B R 14.0%
2021, 21.4% (2021: 21.8%) B R , :
12.8% (2021: 13.8%),
71.9% (2021: 69.3%).

C G , - - , ,

T G , :

	February 28, 2022	December 31, 2021
	(RMB'000)	(RMB'000)
Prepaid expenses and other receivables	339,777	310,090
Employee benefits payable	390,107	321,207
Deferred income	33,584	42,283
Deferred income tax	99,553	75,386
Contract liabilities	63,747	53,470
Trade payables	27,588	25,595
Other payables	85,759	69,081
Contract liabilities, financial instruments	1,040,115	897,112

M 2022 12 31 2021 12 31

D R P , G , RMB1,040.1 , 15.9% 2021. I : () 9.6% ; () 21.5% 32.1% 2021.

F , 32.7% (2021: 34.6%). T 37.5% (2021: 35.8%). T 12.8% (2021: 13.1%).

R T G , D R P , G RMB110.0 , RMB85.5 (2021: RMB51.6).

O T G , D R P , RMB8.1 (2021: RMB23.6), S Y H .

G P G P M D R P , G RMB352.9 , 7.3% 2021. T RMB326.7 , 6.9% 2021. T :

	Feb 2022	Dec 31, 2021
Transportation	27.4%	29.6%
Products	11.6%	10.7%
Other	23.9%	25.4%
People	22.2%	24.7%
Content	23.8%	25.4%

Management Discussion and Analysis

During the reporting period, the Company's operating income increased by 23.8% (2021: 25.4%), and the net profit attributable to shareholders increased by 2.2% (2021: 25.4%). The Company's operating income in 2021 was RMB43.6 million.

Operating Income

During the reporting period, the Company's operating income was RMB5.0 million (2021: RMB5.8 million).

Operating Expenses

During the reporting period, the Company's operating expenses were RMB15.0 million (2021: RMB10.3 million). The Company's operating expenses increased by 1.1% (2021: 0.9%).

Operating Profit

During the reporting period, the Company's operating profit was RMB1.0 million (2021: RMB1.0 million). The Company's operating profit increased by 1.0% (2021: 0.9%). The Company's operating profit was RMB1.0 million (2021: RMB1.0 million).

	For the reporting period ended December 31, 2022 (in MB'000)	2021 (RMB'000)
Operating income	111,252	100,510
Operating expenses	24,761	22,117
Operating profit	29,187	13,014
Operating loss	4,359	2,835
Operating profit	36,328	37,896
Operating profit	205,887	176,372

During the reporting period, the Company's operating profit was RMB205.9 million (2021: RMB13.5 million). The Company's operating profit increased by 16.7% (2021: 25.4%). The Company's operating profit was RMB13.5 million (2021: RMB13.5 million). The Company's operating profit increased by 15.1% (2021: 14.7%).

Management Discussion and Analysis

Reported Period: December 31, 2022 Reported Period: December 31, 2021 Unit: RMB'000		Reported Period: December 31, 2022 Reported Period: December 31, 2021 Unit: RMB'000	
Cash and cash equivalents	18,899	Cash and cash equivalents	16,487
Receivables	9,803	Receivables	8,059
Prepaid expenses and other receivables	4,053	Prepaid expenses and other receivables	3,114
Other assets	273	Other assets	302
Total assets	33,028	Total assets	27,962
Debt	RMB33.0	Debt	(2021: RMB33.0)

Management Discussion and Analysis

During the reporting period, the Company's operating income was RMB44.3 million, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB6.7 million, an increase of 51.1% compared with the same period in 2021. The Company's operating income and net profit were both significantly higher than those of the same period in 2021.

1. Operating Income

Operating income is the total income of the Company's main business activities, including income from the sale of goods, services, and other business activities. The Company's operating income for the reporting period was RMB44.3 million, an increase of 51.1% compared with the same period in 2021.

	For the reporting period 2022 (in MB'000)	For the same period 2021 (RMB'000) (RMB'000)
Sales income	-15,927	-6,566
Cost of sales	18,063	7,075
Depreciation and amortization	714	6,429
	2,850	6,938

During the reporting period, the Company's operating income was RMB2.9 million, an increase of 51.1% compared with the same period in 2021. The Company's operating income was significantly higher than that of the same period in 2021. The Company's operating income was significantly higher than that of the same period in 2021.

2. Cost of Sales

During the reporting period, the Company's cost of sales was RMB25.2 million (2021: RMB2.1 million), an increase of 51.1% compared with the same period in 2021. The Company's cost of sales was significantly higher than that of the same period in 2021.

3. Depreciation and Amortization

During the reporting period, the Company's depreciation and amortization was RMB10.3 million, an increase of 51.1% compared with the same period in 2021. The Company's depreciation and amortization was significantly higher than that of the same period in 2021.

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses

Operating income is the main source of the Company's income. In 2022, the Company's operating income was RMB170.3 million, an increase of 57.3% over 2021. The main reason for the increase is the increase in the number of inpatients and outpatients, and the increase in the average length of stay. The Company's operating expenses were RMB170.3 million, an increase of 57.3% over 2021. The main reason for the increase is the increase in the number of inpatients and outpatients, and the increase in the average length of stay.

	For the year ended December 31, 2022 (in MB'000)	2021 (RMB'000)
General management expenses	55	266
Depreciation and amortization	7,436	9,470
Depreciation of intangible assets	-	1,800
Operating expenses	1,063	300
Non-operating income	8,554	11,836
Losses on disposal of non-current assets	1,588	166
Depreciation of non-current assets	3,928	3,333
Expenses on disposal of non-current assets	1,754	1,399
Expenses on disposal of non-current assets	-	2,000
Operating expenses	2,071	1,739
Non-operating expenses	9,341	8,637

During the reporting period, the Company's operating income was RMB170.3 million, an increase of 57.3% over 2021. The main reason for the increase is the increase in the number of inpatients and outpatients, and the increase in the average length of stay. The Company's operating expenses were RMB170.3 million, an increase of 57.3% over 2021. The main reason for the increase is the increase in the number of inpatients and outpatients, and the increase in the average length of stay.

Income Tax

During the reporting period, the Company's income tax was RMB26.6 million (2021: RMB54.8 million), an increase of 51.5% over 2021. The main reason for the increase is the increase in the number of inpatients and outpatients, and the increase in the average length of stay.

Management Discussion and Analysis

Financial Position

Assets

As of December 31, 2022, the Company's total assets were RMB58.3 million (December 31, 2021: RMB56.5 million), an increase of 3.2%.

Assets

As of December 31, 2022, the Company's total assets were RMB382.8 million (December 31, 2021: RMB311.8 million), an increase of 22.8%. The increase was mainly due to the increase in the balance of the "Prepaid Expenses" account.

During the reporting period, the Company's total assets were RMB42 million (2021: 37 million).

Other Assets and Prepaid Expenses

As of December 31, 2022, the Company's total assets were RMB69.4 million (December 31, 2021: RMB41.8 million).

Other Assets and Prepaid Expenses

As of December 31, 2022, the Company's total assets were RMB63.1 million (December 31, 2021: RMB65.8 million). During the reporting period, the Company's total assets were RMB2.7 million, an increase of 41.2%. The increase was mainly due to the increase in the balance of the "Prepaid Expenses" account.

C

As of December 31, 2022, the Company's total assets were RMB152.5 million (December 31, 2021: RMB43.8 million), an increase of 246.8%. The increase was mainly due to the increase in the balance of the "Prepaid Expenses" account.

R - - A

As of December 31, 2022, the Company's total assets were RMB190.4 million (December 31, 2021: RMB257.4 million), a decrease of 26.0%. The decrease was mainly due to the decrease in the balance of the "Prepaid Expenses" account.

A

As of December 31, 2022, the Company's total assets were RMB85.8 million (December 31, 2021: RMB69.2 million).

Management Discussion and Analysis

Risks Associated with Capital

As of December 31, 2022, the company's total assets were RMB 29.9 million (As of December 31, 2021: RMB16.3 million).

Operating Performance

As of December 31, 2022, the company's operating income was RMB72.2 million (As of December 31, 2021 (As of December 31, 2021): RMB57.3 million), and the company's operating profit was RMB17.0 million (As of December 31, 2021: RMB17.0 million).

Financial Position and Capital

The company's financial position is stable, and the company's capital structure is reasonable. The company's capital structure is reasonable, and the company's capital structure is reasonable.

	Financial Position as of December 31, 2022 (in MB'000)	Financial Position as of December 31, 2021 (in RMB'000)
Net assets	227,221	193,896
Net assets		

N C G F A
 D R P , $RMB116.2$.
 S I A D
 T G R P .
 A G B

A D 31, 2022, RMB553.2), RMB402.7 R P .

 G RMB616.5 (RMB339.4

I have been elected to the Board of Directors of the Company for the term ending on June 13, 2018 (the 2017 AGM). I have been elected to the Board of Directors of the Company for the term ending on June 24, 2021. U.S. Securities and Exchange Commission (SEC) Form 10-K, filed March 29, 2018, and March 30, 2018, and March 14, 2021, and March 18, 2021 and June 25, 2021.

Mit D. A. y.

I E I S , 165 ,
 1,818,529 T . T 23
 , 180,516 T ()
 13 , 540,229 A ,
 8 , 79,274 A ,
 E I S 193 , 2,460,000
 T 3.2976%
 C T 48
 , RMB10.47/ .

T E I S :

(1) P

T E I S
C
G , S , C
C
S
S
C L A A

$$(2) \quad S \quad P_{\mathfrak{A}} \quad \mathfrak{A}$$

(*) S P*

A P G G E I S .

36

() L P E I S

T
B

M 1 D 1 A 1

- (3) D 1 E 1 I 1 S
- (4) F 1 E 1 I 1 S
T C 1 , 1
1 , 1 I 1 S 1
P 1 . W I 1 S 1 P 1 , P 1
1 S 1 C 1 T P 1
1 I 1 S 1 - 1 I 1 S 1
1 P 1
1 T 1
1 U 1 - 1 , P 1
1 I 1 S 1
P 1 .
- () S 1 S 1 E 1 I 1 S
T I 1 S 1 E 1 I 1 S 1 - 1 - D
S 1 , 1 C 1
- () A 1 E 1 I 1 S 1
1 C 1
P 1 2,460,000 S 1 E 1 I 1 S 1 ,
3.30% C 1 , 1
4.45% - 1 - D 1 S 1 .

M 1 D 1 A 1

- (4) V_{I} $\rightarrow$ E_{I} $\rightarrow$ S
- (a) V_{I} $\rightarrow$ E_{I} $\rightarrow$ S
- T $\rightarrow$ E_{I} $\rightarrow$ S 10 $\rightarrow$ E_{I} $\rightarrow$ S
- 2017 (. . A 26, 2018),
- E_{I} $\rightarrow$ S
- () L $\rightarrow$ E_{I} $\rightarrow$ S
- T $\rightarrow$ I $\rightarrow$ S 48 , $\rightarrow$ S
- I $\rightarrow$ S
- () U $\rightarrow$ E_{I} $\rightarrow$ S
- I $\rightarrow$ S 48 (J 28, 2022)
- (J 29, 2018); I $\rightarrow$ S
- E_{I} $\rightarrow$ S
- (5) G_{I} $\rightarrow$ E_{I} $\rightarrow$ S
- () T $\rightarrow$ P_{I} $\rightarrow$ P_{I} $\rightarrow$ P_{I}
- () T C $\rightarrow$ D $\rightarrow$ N $\rightarrow$ G_{I} D
- () T $\rightarrow$ D $\rightarrow$ N $\rightarrow$ C $\rightarrow$
- (V) W $\rightarrow$ C $\rightarrow$ P_{I} $\rightarrow$ C $\rightarrow$
- I $\rightarrow$ S ($\rightarrow$ C $\rightarrow$) $\rightarrow$ C $\rightarrow$
- (V) T C $\rightarrow$ E_{I} $\rightarrow$ S
- $\rightarrow$ P_{I} $\rightarrow$ P_{I} $\rightarrow$ S
- $\rightarrow$ P_{I} $\rightarrow$ $\rightarrow$

M 1 D 1 A 1

- (6) G P E I S S
- (a) G P E I S T G P I S RMB10.47 S ; T G P I S RMB10.47 S .
- () B G P E I S B S , G P RMB10.47 E I S I S

M t D A

F
S
D
31, 2022,
I
S
E
I

N	f G t	B f								
		C P t			I t h			G t ()		
		f h D t			G t G t t t			C L G t t t		
		D t f	D t f G t ()	D t	P t t t	t	t	t	t	D 31,
G t	(H D)	D t	(MB)	1, 2022	P	P	P	P	2022	
D										
M . WANG L	J 18, 2021	35.95	J 28, 2022	10.47	248,328	-	248,328	-	-	-
M . WANG H ()	J 18, 2021	35.95	J 28, 2022	10.47	95,511	-	95,511	-	-	-
S										
M . SUN F ()	J 18, 2021	35.95	J 28, 2022	10.47	14,327	-	14,327	-	-	-
M . XIE T	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-
O										
M . XU Y (M . WANG H)	J 18, 2021	35.95	J 28, 2022	10.47	28,653	-	28,653	-	-	-
M . WANG B (M . WANG L)	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-
M . XU Q (M . XU Y)	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-
M . GUAN W ()	J 18, 2021	35.95	J 28, 2022	10.47	19,102	-	19,102	-	-	-
M . SUN H (M . WANG L)	J 18, 2021	35.95	J 28, 2022	10.47	30,563	-	30,563	-	-	-
M . WANG H ()	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-
M . ZHANG L (-)	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-
M . GUAN W ()	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-	-

Report of the Board

The Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has reviewed the financial statements of the Company for the year ended December 31, 2022.

The Board of Directors of the Company has approved the financial statements of the Company for the year ended December 31, 2022.

The Board of Directors of the Company has approved the financial statements of the Company for the year ended December 31, 2022. The Board of Directors of the Company has approved the financial statements of the Company for the year ended December 31, 2022. The Board of Directors of the Company has approved the financial statements of the Company for the year ended December 31, 2022.

C R L R

T C , ,
PRC C L , H K L R , SFO, H K C O ,
S , , C T C
B D .

L G M
H L PRC (《中華人民共和國精神衛生法》), L P ' R C P
B M H G (《中華人民共和國基本醫療衛生與健康促進法》) (J 1, 2020),
M R M I (《醫療機構管理條例》 R I
M R M I (《醫療機構管理條例實施細則》).

T G . I
.

T C . T D
G 2022 L P D .

P I P

F D 31, 2022, G .

U P I P O

Report of the Board

Dv

T B S D 31, 2022.

T R E

I E I T L P ' R C 《中華人民共和國企業所得稅法》
J 1, 2008, C
10% - S
H S . A H S
S , HKSCC N L , ,
S - S . T ,
S . I H S
S . T C
S H S

I V H S H K M PRC S C 10% S 10% PRC S 10% I C H S S 10% S C H K I S L T C S H S 20% PRC C I PRC C 20% PRC C

Report of the Board

DIRECTORS' REPORT

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has completed its duties in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following report.

EXECUTIVE SUMMARY

For the period from January 1, 2022, to December 31, 2022, the Company has completed its business operations in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following report.

DEBTS

For the period from January 1, 2022, to December 31, 2022, the Company has completed its business operations in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following report.

SUBSIDIARIES

During the period from January 1, 2022, to December 31, 2022, the Company has completed its business operations in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following report.

DI

The Board of Directors has completed its duties in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following report.

EXECUTIVE SUMMARY

M. GUAN W (Chairman)

M. WANG L (Vice Chairman)

M. WANG H (Secretary) (Term expires December 31, 2022)

NON-EXECUTIVE DIRECTORS

M. QIN H

M. LI C

INDEPENDENT NON-EXECUTIVE DIRECTORS

M. ZHONG W

M. LIU N

M. ZHAO X (Term expires March 10, 2023)

S

T S R P :

M . XUN (C) (F ,19, 2022)

M . XU Y

M . XIE T

M . QIAN C

M . SUN F (C) (F ,15, 2022)

M . CHEN J (,17, 2022)

B R A K I F P

F , G D 31, 2022, F H M D A

D ' S ' I T , A C

S R B - C T N F S - R
C ,
D S , D S ,
D 31, 2022 R P .

C S ' I C S

S R B - C T N F S - R
C S
G C

M C

D R P , C
C

Report of the Board

N - A

P / N - A , C S , , G , D N - A D 31, 2022, C P O N (S R C S P) C S .


T C A D D 31, 2022. C S 31, 2022 S , N - T A N -

D
E

P D , N F S - R C G

D 31, 2022 N F S - R C G

R . T C G

N D  R P .

D ' I C B

D R P , D H K L

$$\begin{array}{ccccccc}
 & & & & & & A \dots t \\
 & & & & & & | \\
 & & & & & & A \dots t \quad p \dots t \quad f \\
 & & & & & & | \\
 & & & & & & p \dots t \quad h \quad C \quad y' \\
 & & & & & & | \\
 & & & & & & h \dots f \quad h \quad t \quad I, \\
 & & & & & & | \\
 N \dots & C \dots f \quad h \dots & N \quad t \dots f \quad I \quad t \dots t & & N \dots f \quad h \dots & f \quad h \dots & C^{(1)} \quad h \quad C \quad t^{(1)}
 \end{array}$$

Report of the Board

I. Shareholder Structure

As of December 31, 2022, the Company has 336 shareholders, including 100 institutional investors and 236 individual investors. The Company is listed on the Shanghai Stock Exchange (SSE) under the ticker symbol 603013. The Company's shares are traded on the SSE. The Company's shares are listed on the SSE under the ticker symbol 603013. The Company's shares are listed on the SSE under the ticker symbol 603013.

			A . . . t A . . . t		
			P . . . t P . . . t		
			h . . . f h C . . . y'		
			N . . . f h . . . t I . . .		
N	C . . . f h . . .	N . . . t . . . f I . . . t . . .	h	C . . . (1) h	C . . . t . . . (1)
C . . . E . . . R . . . I . . . y	D . . .	S . . . B . . .	7,466,666(L)	13.51%	10.00%
I y . . . F . . . C . . . , L . . . (中央企 業鄉村產業投資基金股份有限公司) (C . . . E . . . F . . .)					
S . . . J . . . E . . . M . . .	D . . .	S . . . I . . .	4,540,000(L)	8.22%	6.09%
C . . . (L . . . P . . .) (上海 金浙企業管理中心(有限合夥)) ⁽²⁾					
FAN Y . . . ⁽²⁾	D . . .	S . . . I . . .	4,540,000(L)	8.22%	6.09%
SUN J . . . ⁽²⁾	D . . .	S . . . I . . .	4,540,000(L)	8.22%	6.09%
S . . . J . . . J . . . E . . . y	D . . .	S . . . I . . .	4,540,000(L)	8.22%	6.09%
I y . . . M . . . C . . . , L . . . (上海金浦健服股權投資管理有限公 司) ⁽²⁾					
W . . . J . . . E . . . I y	D . . .	S . . . B . . .	4,540,000(L)	8.22%	6.09%
P . . . (L . . . P . . .) (溫州金寧股權投資合夥企業(有限 合夥)) (J . . . I y)					
XU Y . . . ⁽⁶⁾	D . . .	S . . . I . . .	5,785,350(L)	10.47%	7.76%
S . . . T . . . I y	L.P. (上 D . . .	S . . . B . . .	4,519,003(L)	8.18%	6.06%
海檀英投資合夥企業(有限合夥))					

	Absolute Percentage	Attributable Percentage	Attributable Percentage
	Percentage of Total Investment	Percentage of Total Investment	Percentage of Total Investment
Name of the Company	Investment Amount (RMB)	Percentage of Total Investment (%)	Percentage of Total Investment (%)
Sinohydro Shanghai Leasing Investment Co., Ltd. (上海樂進投資合夥企業(有限合夥)) ⁽³⁾	4,519,003(L)	8.18%	6.06%
LIN L	6,506,309(L)	11.77%	8.72%
Sinohydro Shanghai Vast Investment Management Co., Ltd. (上海正心谷投資管理有限公司) (Sinohydro Shanghai Vast Investment Management Co., Ltd.) ⁽⁴⁾	6,506,309(L)	11.77%	8.72%
Wangyi Information Technology Co., Ltd. (萬得信息技術股份有限公司)	3,333,000(L)	6.03%	4.47%
Sinohydro Huateng Enterprise Management Center (Shanghai Huateng Enterprise Management Center (Limited Partnership)) (上海荷花緣企業管理中心(有限合夥))	3,333,000(L)	6.03%	4.47%
Wangyi E-Influence Investment (Jiaxing) Co., Ltd. (L) (萬得影響力股權投資(嘉興)合夥企業(有限合夥)) (Wangyi E-Influence Investment (Jiaxing) Co., Ltd.)	3,333,000(L)	6.03%	4.47%
Qingdao Jinshi Yanna Investment Co., Ltd. (青島金石灝汭投資有限公司)	2,780,000(L)	5.03%	3.73%
Jinshi Investment Co., Ltd. (金石投資有限公司) ⁽⁵⁾	2,780,000(L)	5.03%	3.73%
O.M.A. LLC	1,454,000(L)	7.52%	1.95%
O.M.C. LLC	2,150,900(L)	11.12%	2.88%
O.M.P. M.F.	1,279,900(L)	6.62%	1.72%
L			
O.M.P. II, L.P.	1,052,000(L)	5.44%	1.41%
UBS G AG	1,029,400(L)	5.32%	1.38%
ZOU He (鄒海麗)	1,680,000(L)	8.69%	2.25%

Report of the Board

N :

(L): L

- (1) T 55,260,000 D S 19,340,300 H S (74,600,300 S) C D 31, 2022.
- (2) FAN Y 50% S J E M C (L P) (上海金浙企業管理中心(有限合夥)) S J E M C (L P) (上海金浙企業管理中心(有限合夥)) W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). SUN J 33.94% W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). S J J E I M C , L . (上海金浦健服股權投資管理有限公司) W J E I P (L P). T , XV SFO, FAN Y , S J E M C (L P) (上海金浙企業管理中心(有限合夥)), SUN J S J J E I M C , L . (上海金浦健服股權投資管理有限公司) D S W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)) C
- (3) S L I L.P. (上海樂進投資合夥企業(有限合夥)) 99.99% S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L I L.P. (上海樂進投資合夥企業(有限合夥)) D S S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (4) S L V I M C , L (上海正心谷投資管理有限公司) (S S I M C , L (上海盛歌投資管理有限公司)) S Q I M P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L V I M C , L D S S Q I M P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) (1,987,356 D S C S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (5) Q J H I C , L . (青島金石灝沏投資有限公司) J I C , L . (金石投資有限公司). T , J I C , L . (金石投資有限公司) D S Q J H I I C , L . (青島金石灝沏投資有限公司) C J XV SFO.
- (6) M . WANG H J N X K I M L.P. N E K I M P (L P) 50.62% 37.10%, , XV SFO, M . WANG H J D S M . XU Y M . WANG H . M . XU Y D S M . WANG H J XV SFO.

S , D 31, 2022, D , (D , S C , D 2 3 S S C J D XV SFO, C S 336 SFO.



T (BDO), BDO C, S, L, P, C, P, A, LLP

A D 16, 2022, BDO A C B 2021 C H S C C 2022 PRC A S , B E , C 2022 C

F       , 

Report of the Board

(2) C B S 2020

(Unit: RMB,)

Item	At the end of the period	Change	Balance at the end of the period
Operating income	63,465,824	-12,878	63,478,702
Operating expenses	542,683,617	-12,878	542,696,495
Operating profit	2,161,261,775	-12,878	2,161,274,653
Other income	76,603,400	-9,203,741	85,807,141
Other expenses	606,077,103	-9,203,741	615,280,844
Other profit	946,349,216	-9,203,741	955,552,957
Unrealized gains	214,856,099	9,190,863	205,665,236
Total	1,122,247,550	9,190,863	1,113,056,686
Total	1,214,912,559	9,190,863	1,205,721,695
Total	2,161,261,775	-12,878	2,161,274,653

(3) C F S 2021

(Unit: RMB,)

Item	At the end of the period	Change	Balance at the end of the period
Operating income	29,925,488	-12,878	29,938,366
Operating expenses	609,602,623	-12,878	609,615,501
Operating profit	2,377,954,989	-12,878	2,377,967,867
Other income	57,319,524	-9,203,741	66,523,265
Other expenses	535,774,635	-9,203,741	544,978,376
Other profit	1,097,675,868	-9,203,741	1,106,879,609
Unrealized gains	6,937,845	-12,878	6,950,723
Unrealized losses	257,098,624	9,190,863	247,907,761
Total	1,208,263,897	9,190,863	1,199,073,034
Total	1,280,279,120	9,190,863	1,271,088,257
Total	2,377,954,989	-12,878	2,377,967,867

Opinions of the Independent Non-executive Directors

T
- 56
C
A
S
B
E
C
T
T
T

Opinions of the Board

T B
C
C
T B
A
A
C
A
C
T B

Opinions of the Supervisory Committee

T S
C
C
T S
C

Opinions of the Audit Committee

T A C
S B E
C
T A C
N XV F S -O

C S T

F ♀ ♀ B ♀
GUAN W
C ♀ ♀

Z , PRC
A 14, 2023

T S :

I 2022, S C , PRC C L , A ,
S C , T B , S
C ,
D C S .

D R P , S C B , C
C C

T S C - C R
P , D B ,

I 2023, S C -
. T , S C
, S C

F S C
XUN
C

Z , PRC
A 14, 2023

Corporate Governance Report

The Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (hereinafter referred to as "the Company") is committed to the corporate governance, and has established a complete corporate governance system. The Company has established a Board of Directors, a Board of Supervisors, and a Management Team, and has implemented a system of checks and balances. The Company has also established a system of internal control, and has implemented a system of risk management. The Company has also established a system of information disclosure, and has implemented a system of investor relations. The Company has also established a system of employee relations, and has implemented a system of employee training. The Company has also established a system of social responsibility, and has implemented a system of social contribution.

Board of Directors

Board of Directors

The Board of Directors of the Company is composed of 9 members, including 3 independent non-executive directors and 6 executive directors. The Board of Directors is responsible for the overall management of the Company, and for the formulation and implementation of the Company's strategic management. The Board of Directors has established a system of internal control, and has implemented a system of risk management. The Board of Directors has also established a system of information disclosure, and has implemented a system of investor relations. The Board of Directors has also established a system of employee relations, and has implemented a system of employee training. The Board of Directors has also established a system of social responsibility, and has implemented a system of social contribution.

The Board of Directors of the Company has established a system of internal control, and has implemented a system of risk management. The Board of Directors has also established a system of information disclosure, and has implemented a system of investor relations. The Board of Directors has also established a system of employee relations, and has implemented a system of employee training. The Board of Directors has also established a system of social responsibility, and has implemented a system of social contribution.

The Board of Directors of the Company has established a system of internal control, and has implemented a system of risk management. The Board of Directors has also established a system of information disclosure, and has implemented a system of investor relations. The Board of Directors has also established a system of employee relations, and has implemented a system of employee training. The Board of Directors has also established a system of social responsibility, and has implemented a system of social contribution.

The Board of Directors of the Company has established a system of internal control, and has implemented a system of risk management. The Board of Directors has also established a system of information disclosure, and has implemented a system of investor relations. The Board of Directors has also established a system of employee relations, and has implemented a system of employee training. The Board of Directors has also established a system of social responsibility, and has implemented a system of social contribution.

The Board of Directors of the Company has established a system of internal control, and has implemented a system of risk management. The Board of Directors has also established a system of information disclosure, and has implemented a system of investor relations. The Board of Directors has also established a system of employee relations, and has implemented a system of employee training. The Board of Directors has also established a system of social responsibility, and has implemented a system of social contribution.

Corporate Governance Report

REPORT OF THE BOARD OF DIRECTORS

The Board of Directors has completed its work in 2022. The Board has reviewed the company's financial statements and the internal control system, and has confirmed that the company's financial statements are true and accurate, and the internal control system is effective. The Board has also reviewed the company's business performance and the implementation of its business strategy, and has confirmed that the company's business performance is good, and the implementation of its business strategy is in line with the company's long-term development strategy.

The Board has also reviewed the company's environmental, social and governance (ESG) performance, and has confirmed that the company's ESG performance is good, and the implementation of its ESG strategy is in line with the company's long-term development strategy. The Board has also reviewed the company's risk management system, and has confirmed that the company's risk management system is effective.

The Board has also reviewed the company's human resources management system, and has confirmed that the company's human resources management system is effective. The Board has also reviewed the company's information disclosure system, and has confirmed that the company's information disclosure system is effective.

The Board has also reviewed the company's corporate governance system, and has confirmed that the company's corporate governance system is effective. The Board has also reviewed the company's internal audit system, and has confirmed that the company's internal audit system is effective.

The Board has also reviewed the company's legal affairs management system, and has confirmed that the company's legal affairs management system is effective. The Board has also reviewed the company's compliance management system, and has confirmed that the company's compliance management system is effective.

REPORT OF THE SUPERVISORY BOARD

Corporate Governance Report

Chairman of the Board, Supervisors, and Directors

On December 31, 2021, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (hereinafter referred to as "Company") held its 2021 Annual Meeting, electing Mr. WANG HONG as Chairman of the Board, Mr. JIN HONG as Vice Chairman, and Mr. CHEN JIAN as Secretary of the Board.

On January 17, 2022, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. held its 2022 Annual Meeting, electing Mr. CHEN JIAN as Chairman of the Board, Mr. JIN HONG as Vice Chairman, and Mr. CHEN JIAN as Secretary of the Board.

On February 15, 2022, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. held its 2022 Annual Meeting, electing Mr. SUN FENG as Chairman of the Board, Mr. JIN HONG as Vice Chairman, and Mr. CHEN JIAN as Secretary of the Board.

On February 19, 2022, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. held its 2022 Annual Meeting, electing Mr. XUN MING as Chairman of the Board, Mr. JIN HONG as Vice Chairman, and Mr. CHEN JIAN as Secretary of the Board.

On July 12, 2022, Mr. NG WING SANG, Chairman of the Board, and Mr. NG WING SANG, Chairman of the Board, held a meeting with the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (hereinafter referred to as "Company") to discuss the Company's 2022 Annual Meeting. The meeting was held on July 12, 2022, at the Company's headquarters, 4T) C, H KH, 4T T 0 16 C, DO, 622 C, L D KH.

On July 5, 2023, C. WANG L. (M.), D., M. W. 100,000 S C M. W. J., C RMB13.28 S D 19, 2022 (D.). P D, M. W. / B D C A M. W. S C B - P C C D C, C M. W. , A.3 B.8 M C.

Corporate Governance Report

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

- (1) 报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。
- (2) 报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。
- (3) 报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规及规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

Corporate Governance Report

C

O Ma 10, 2023, M. ZHAO X
- 5% D C B .F M. ZHAO X ,
N C B .F M. ZHAO X ,
- 5% D C H K
L R : () B C - 5% R 3.10
H K L R ; () - 5%
R 3.25 H K L R ; ()
- 5% R 3.27A H K L R . O Ma 10, 2023, B
C M. JIN L - 5% D
C R C B , N C
B .A C M. JIN L
- 5% D .F , C Ma 10, 2023.

S , B CG C R P .

S C D S

E D (- 5% D) S
C .

T D S A , . N
C , C .

A S

T C C A S B E 2017,
C O (C 622 H K) (C O) .

A P

A , t P

T A S B E - B
S , M F
F 15, 2006 (A , t f B
E t) .

T . T H K C O
Ma 3, 2014. C
H K C O .

Corporate Governance Report

$$Ch \quad f \quad f \quad tA \quad , \quad t \quad p$$

T ♀ ♀ ♀ ♀ N III (XXXI) F ♀ ♀ S ♀ - S ♀

♀ ♀ ♀ ♀ ♀ ♀

A B M G M

T C B C.5.1 CG C . N B C.5.3 CG

D R P , C 11 B D B

$$N_{\text{eff}} = f D_{\text{eff}} / t_{\text{eff}} \quad \text{and} \quad B_{\text{eff}} = t_{\text{eff}} / t_{\text{eff}} = 1$$

E . . . t . . . D . . . t . . .

M . GUAN W (C 禁 禁)	11/11
M . WANG L 禁 禁	11/11
M . WANG H 禁 (S 1, 2022)	5/5

N - , **t** **D** , **t**

M. QIN H	11/11
M. LI C	11/11

I t - t D t

M . ZHAO X	(	M	10, 2023)	11/11
M . ZHONG W				11/11
M . LIU N				11/11

A D          . T   , , C C

Figure 1 displays Feynman diagrams for the decay of a scalar particle M into two photons. The diagrams are arranged in two rows. The top row shows diagrams for the decay $M \rightarrow \gamma\gamma$ via a loop of a charged scalar particle B . The bottom row shows diagrams for the decay $M \rightarrow \gamma\gamma$ via a loop of a charged fermion T . Each diagram is labeled with its corresponding particle or loop type: M , B , T , D , and various combinations of these labels indicating the internal lines and vertices.

姓名 / 姓名拼音	职称 / 职务
教育部直属单位	
M. GUAN W (中国科学院)	1/1
M. WANG L (中国科学院)	1/1
M. WANG H (中国科学院, 2022)	0/0
国家自然科学基金委员会	
M. QIN H (中国科学院)	1/1
M. LI C (中国科学院)	1/1
中国科学院大学	
M. ZHAO X (中国科学院, 2023)	1/1
M. ZHONG W (中国科学院)	1/1
M. LIU N (中国科学院)	1/1

Corporate Governance Report

B 董事

本公司董事会由5名董事组成，其中独立董事3名，非独立董事2名。董事会下设审计委员会、薪酬与考核委员会、提名委员会、战略委员会、风险管理委员会等专门委员会。董事会负责公司的经营决策，监督经理层的工作，并对公司的发展战略、重大投资、财务预算、利润分配等事项进行审议和批准。董事会还负责公司的内部控制体系建设，确保公司运营的合法合规性。

A 高级管理人员

本公司高级管理人员包括总经理、副总经理、财务总监、董事会秘书等。高级管理人员负责公司的日常经营管理，执行董事会的决议。总经理负责公司整体运营，副总经理协助总经理工作。财务总监负责公司的财务管理，董事会秘书负责公司的信息披露和投资者关系管理。高级管理人员的聘任和解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会制定，并经董事会批准。

本公司高级管理人员的任职资格符合相关法律法规的要求。高级管理人员在任职期间，应勤勉尽责，忠实履行职务。高级管理人员的考核由董事会负责，考核结果作为其薪酬发放的重要依据。高级管理人员应定期向董事会报告工作，并接受董事会的监督。

本公司高级管理人员的变动情况如下：

姓名	职务	任期
M. ZHONG W	董事长	2021年12月 - 2023年12月
M. LIU N	总经理	2021年12月 - 2023年12月
M. LI C	财务总监	2021年12月 - 2023年12月

M. ZHONG W (C 董事)	5/5
M. LIU N	5/5
M. LI C	5/5

Corporate Governance Report

一、公司治理

本公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

姓名	职务	任期起止日期
M. LIU N (C 董 事)	董事	2/2
M. GUAN W	董事	2/2
M. ZHAO X (独 立 董 事)	独立董事	2/2

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号—主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项治理制度，提高公司治理水平，保障股东和投资者的合法权益。

Corporate Governance Report

R C

T C R C R C B . T CG C
R C R C D
D
D
;
,
/ D
D
B .
C 17 H K L R ;
C

A, R C - D, M. ZHONG W M. LIU N. T R C E.1.2() CG C (. . B D). O R C R P, C 2021.

[illegible]

N **f**
t

D. . . . t

/ tt

M. ZHAO X (C. A.) (M. 10, 2023)

1/1

M. ZHONG W

1/1

M. LIU N

1/1

T  G  D  C 
  /  . T 
D  -  D  ,  - 
 B  .

T D 31, 2022 N F S -

Corporate Governance Report

S  R  C

T C   S  R  C

Corporate Governance Report

董事會、監事會及高級管理人員

年齡	性別	學歷	專業資格
30 – 49 (3)	男 (33.3%)	1 – 5 (4)	
50 – 59 (3)	女 (66.7%)	6 – 10 (2)	

截至 2022 年 12 月 31 日，本公司共有 6 名董事，其中獨立非執行董事 3 名，佔董事總數的 50%。本公司共有 3 名監事，其中獨立非執行監事 1 名，佔監事總數的 33.33%。本公司共有 6 名高級管理人員，其中獨立非執行高級管理人員 1 名，佔高級管理人員總數的 16.67%。

董事會及監事會成員

截至 2022 年 12 月 31 日，本公司共有 6 名董事，其中獨立非執行董事 3 名，佔董事總數的 50%。本公司共有 3 名監事，其中獨立非執行監事 1 名，佔監事總數的 33.33%。本公司共有 6 名高級管理人員，其中獨立非執行高級管理人員 1 名，佔高級管理人員總數的 16.67%。

董事會及監事會成員

截至 2022 年 12 月 31 日，本公司共有 6 名董事，其中獨立非執行董事 3 名，佔董事總數的 50%。本公司共有 3 名監事，其中獨立非執行監事 1 名，佔監事總數的 33.33%。本公司共有 6 名高級管理人員，其中獨立非執行高級管理人員 1 名，佔高級管理人員總數的 16.67%。

截至 2022 年 12 月 31 日，本公司共有 6 名董事，其中獨立非執行董事 3 名，佔董事總數的 50%。本公司共有 3 名監事，其中獨立非執行監事 1 名，佔監事總數的 33.33%。本公司共有 6 名高級管理人員，其中獨立非執行高級管理人員 1 名，佔高級管理人員總數的 16.67%。

T C . A . T . T . W G . A .



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

Corporate Governance Report

SUBSIDIARY INFORMATION

The Company has established a subsidiary, Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.), which is a subsidiary of the Company. The subsidiary was established on December 31, 2022.

Number of Shares Held (MB)	Percentage of Total Shares (%)
0-700,000	1
700,001-1,400,000	6

ASSOCIATED INFORMATION

For the period ending December 31, 2022, the Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company.

The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company.

The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company.

JUDICIAL INFORMATION

The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company.

The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company.

The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., has a total of 1,400,000 shares, which is 1.4% of the Company's total shares. The Company's subsidiary, Wenzhou Kangning Hospital Co., Ltd., is a subsidiary of the Company.

Corporate Governance Report

C S I R

T B                              

T C S ' C P S ' P

T C B B B

S . C B , B ,

B B ,

D R P , C P C , . . I

T B S C S ' C P

S $\rightarrow$ R

P... f h h ...) t C ... E t ... y G ... M t (EGM)
S... EGM ...

S $\rightarrow$ B, $\rightarrow$ EGM 10% S $\rightarrow$ A, $\rightarrow$ EGM
 A, B $\rightarrow$ EGM

I B    EGM   ,         
B    . C           
S  .

I B, S, EGM, 10% S, C, EGM.

S    B   C  

Corporate Governance Report

C 董 C 董 D

D R P , A .

D P

T C 10% C C 50% C S C , A C , A C S A . S C N S

T C ():

(I) ;

(II) ;

(III) , , , ,

T C RMB S . S C S RMB HKD. S HKD S

T B C

M. G. A. (管偉立), 53, B. D. H. C. H. C. F. 1996

Directors, Supervisors and Senior Management

Non-Executive Directors

M. QIN H (秦浩), 32, Male, Bachelor's Degree, G J 2021. H (上海正心谷投资管理有限公司), S L V I M C., L (上海正心谷投资管理有限公司), J 2022. H S L V I M C., L J 2017 D 2021.

M. Q P U J 2014 . H F U J 2017 .

M. LI Ch h (李昌浩), 33, Male, Bachelor's Degree, G O 2021. H SDIC C I F M C., L . (國投創益產業基金管理有限公司) J 2022, . H SDIC C I F M C., L . M 2014 D 2021. H Y A C., L . (雲南鋁業股份有限公司), S S

M. (許寧), 49, S. C. H. M. X. C. Ma 2016, C. H. Ma 2016
O 2016, M. X. F. N. 2016 D
2017, H. J. 2022. H. J. 2022. H. C. W. TV S (溫州電視台)
J. 2022. H. J. 2022. H. C. W. N
(《溫州新聞聯播》), S. 1998 F. 2016,

Directors, Supervisors and Senior Management

M. X. (中國傳媒大學)) J. 1998, (一級人力資源管理師) M. H. R. S. S. P., R. C. F. 2018.

M. (徐永久), 45, S. H. C. O. 2021, S. A. 2023, S. J. J. E. I. Ma. C., L. (上海金浦健服股權投資管理有限公司) S. J. 2021, (溫州金寧股權投資合夥企業(有限合夥)). S. J. 19, 2018, C. Y. H. C., L. (成都怡寧醫院有限公司). S. F. 2016, S. Y. I. C., L. (上海銀驛投資有限公司). F. J. 2004 D. 2007, D. R. H. S. I. G. F. D. 2007 Ma. 2009, I. B. H. A. P. C. F. Ma. 2009 S. 2011, S. I. G. S. I. H. S. T. F. O. 2011 O. 2015, M. X. GP G. C., L. (金浦產業投資基金管理有限公司). F. A. 2016 Ma. 2023, S. J. J. E. I. Ma. C., L. (上海金浦健服股權投資管理有限公司).

M. X. S. U. F. E. J. 2000. H. F. U. J. 2004. S. J. 2015, S. L. S. F. U. H. C. E. I. B. S. EMBA (E. Ma. B. A.) N. 2022.

M. QIAN (錢成良), 72, S. H. C. J. 2017, S. P. C. Ma. 2007 Ma. 2012, S. S. U. 8.15

Directors, Supervisors and Senior Management

S Ma

M. ZHO (周朝毅), 60, C M. Z C F 2005
 . H S 2014
 C P C N 1995
 D 2004, M. Z W C H (温州心血管醫院)
 W, . F Ma, 1990 O 1995, M. Z
 (

Directors, Supervisors and Senior Management

M. 徐 (徐誼), 48, . H . C M . X C O 2002 (科長) O 2002 Mar 2009, . F A 2009 S 2014, C H P S 2014 C P

M 5B12190CFB0D8

Directors, Supervisors and Senior Management

M、INH（金輝），36，.H
H C J 2022 .P C
L（浙江華明會計師事務所有限公司）F 2012 D 2021，
W ;
M P ' C N 2018，
.P Z H C P A C L，
W L C P A C L（溫州立德會計師事務所有限公司）

Directors, Supervisors and Senior Management

Director / Supervisor	Position	Gender	Age	Education	Work Experience	Start Year
XU Y	Chairman	Male	58	Master's Degree	1980s	2011
Q K	Chairman	Male	58	Master's Degree	1980s	2013
Y K	Chairman	Male	58	Master's Degree	1980s	2014
S Y	Chairman	Male	58	Master's Degree	1980s	2015
W Y	Chairman	Male	58	Master's Degree	1980s	2015
B Y	Chairman	Male	58	Master's Degree	1980s	2015
S Y	Chairman	Male	58	Master's Degree	1980s	2015
Q Y	Chairman	Male	58	Master's Degree	1980s	2015
Z H	Chairman	Male	58	Master's Degree	1980s	2016
T K	Chairman	Male	58	Master's Degree	1980s	2016
Z K	Chairman	Male	58	Master's Degree	1980s	2016
H Y	Chairman	Male	58	Master's Degree	1980s	2017
T L	Chairman	Male	58	Master's Degree	1980s	2016
H K	Chairman	Male	58	Master's Degree	1980s	2018
H C	Chairman	Male	58	Master's Degree	1980s	2017
W T	Chairman	Male	58	Master's Degree	1980s	2018
W T	Chairman	Male	58	Master's Degree	1980s	2018
Z J	Chairman	Male	58	Master's Degree	1980s	2018
T J	Chairman	Male	58	Master's Degree	1980s	2020
W J	Chairman	Male	58	Master's Degree	1980s	2021
W Y	Chairman	Male	58	Master's Degree	1980s	2022

D...t / ... P...t H...t
M...t M...f b G ,

Directors, Supervisors and Senior Management

D. t. / M. t.	M. f. b. G.	P. t. H. t.	M. f. b. G.	M. f. Off.
ZHANG F	L. K. H. C., L.	E. M.	F. J. 2018	
	W. N. P. S. H. C., L.	D.	F. J. 2019	
	L. C. H. C., L.	E. M.	F. D. 2020	
YE M	W. Y. H. T. C., L.	E. M.	F. M. 2019 J. 2022	
JIN W	Q. Y. H. C., L.	D.	F. N. 2015	
	H. Y. P.	D.	F. D. 2018	
	H. C., L.	P. C. Y.	E. M.	F. S. 2021
	C. Y. N. C. C., L.	E. M.	F. M. 2021	
		G. G.	F. D. 2022	
XUN	G. Y. H. C., L.	E. M.	F. J. 2019	
	H. Y. P. H. C., L.	C. G.	F. M. 2020	
JIN H	W. O. Y. E. H. C., L.	S. M.	F. S. 2022	
	C. Y. N. C. C., L.	S. M.	F. S. 2022	

A t ,

X K S B Z [2023] N .ZA12856

h h h f h , H t C ., Lt .,

I. O

[illegible]

I
E (CAS).

II. Background

W $\rightarrow$ C S A (CSA). O
A ' R A F S

Appendix

III. K&A Management

K&A Management is a key part of the company's management system. It is responsible for the company's overall strategy, business plan, and financial management. The K&A Management team is composed of senior management and professional staff. They are responsible for the company's overall strategy, business plan, and financial management. They are also responsible for the company's overall strategy, business plan, and financial management.

Answer

Year	Month	Hour	Day	Time
1.	D			



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

A t ' t

A. t ,

IV. O I

M₂ K₂ H (M₂)
 . T 2022 K₂
 H . K₂ H , 2022

O
 .

I ,
 , , ,
 .

W K₂ H , 2022 A R ,
 , .

V. R M T C G

T M₂
 CAS ,
 , .

I , W K₂ H ,
 , , ,
 M₂ W K₂ H
 , .

T W K₂ H ,

A. t_0

VI. A

C **t** **B** **h** **t** A 31 D 2022

A E	N V	D 31, 2022	D 31, 2021 (R)	J 31, 2021 (R)
C t t:				
G S P	(I)	271,094,962.97	188,734,845.77	206,499,564.42
F D N A R A P R P O F I C A N O	(II)	10,641,026.00	10,000,000.00	
	(III)	382,836,690.89	311,757,875.46	225,300,247.01
	(VI)	32,201,223.97	11,858,427.06	9,909,510.16
	(V)	37,195,219.68	29,925,487.99	63,465,823.77
	(VI)	58,331,397.37	56,519,301.23	37,508,471.39
	(VII)	752,324.77	806,685.85	
t t t		793,052,845.65	609,602,623.36	542,683,616.75
N t t:				
G D O L L I O I F	(VIII)	14,000,000.00		
	(IX)	143,546,246.10	129,847,779.24	97,816,933.76
	(X)	63,116,852.05	65,812,274.58	57,404,918.27
				107,804,936.40

截至2022年12月31日止年度 (人民币千元)			
资产负债表	2022	2021	2021
LIABILITY AND EQUITY	2022	2021	2021
		(RMB '000)	(RMB '000)
Current liabilities:			
Short-term borrowings	(XIX) 203,000,000.00	254,050,000.00	312,500,000.00
Bank borrowings			

C **t** **B** **h** **t** A 31 D 2022

LIABILITIES AND EQUITY	NOV	DEC 31, 2022	DEC 31, 2021	JAN 1, 2021
			(RMB)	(RMB)
Current liabilities:				
Short-term borrowings	(XXXIII)	74,600,300.00	74,600,300.00	74,600,300.00
Other payables				
Payables to related parties				
Payables to other parties				
Guaranteed payables	(XXXIV)	855,078,533.30	838,165,395.59	819,509,065.54
Long-term payables				23,311,143.84
Other payables				
Short-term payables	(XXXV)	38,399,577.13	38,399,577.13	36,593,228.71
Long-term payables				
Other payables	(XXXVI)	233,506,534.43	257,098,624.31	214,856,099.61
Long-term liabilities:				
Long-term payables		1,201,584,944.86	1,208,263,897.03	1,122,247,550.02
Non-current liabilities		124,317,673.97	72,015,223.54	92,665,008.81
Current liabilities		1,325,902,618.83	1,280,279,120.57	1,214,912,558.83
TOTAL LIABILITIES		2,637,787,406.99	2,377,954,988.76	2,161,261,774.68

TOTAL ASSETS

L
GUAN W

P
JIN H

H
WANG M

	D. 31, 2022	D. 31, 2021	J. 31, 2021
A. E'	N. XVI	(R.)	(R.)

资产负债表 截至2022年12月31日 (人民币元)

资产负债表	截至2022年12月31日	截至2021年12月31日	截至2021年12月31日
所有者权益	2022	2021	2021
所有者权益	(人民币元)	(人民币元)	(人民币元)
流动资产：			
货币资金	195,000,000.00	251,050,000.00	310,000,000.00
应收账款			
预付款项			
其他应收款			
存货			
流动资产合计	20,689,401.73	13,161,555.37	34,954,083.13
非流动资产：			
长期股权投资	3,299,924.90	2,011,708.12	
固定资产			3,480,241.45
无形资产	18,740,841.95	17,876,433.39	15,629,765.62
递延所得税资产	597,972.12	4,848,233.63	8,267,930.79
其他非流动资产	49,473,505.95	74,941,835.88	27,298,927.14
非流动资产合计	91,487,500.00	3,000,000.00	
流动资产合计	379,289,146.65	366,889,766.39	399,630,948.13
非流动资产合计			
长期股权投资	284,750,000.00	200,950,000.00	38,000,000.00
固定资产			
无形资产			
递延所得税资产			
其他非流动资产			
非流动资产合计	25,922,687.47		
流动资产合计			
长期股权投资			
固定资产			
无形资产			
递延所得税资产			
其他非流动资产			
非流动资产合计	9,037,891.00	9,341,683.00	9,645,475.00
流动资产合计	2,291,279.89	2,853,156.89	1,607,648.32
非流动资产合计			

LIABILITE AND HOLDERS' EQUITY	December 31, 2022	December 31, 2021	January 1, 2021
	(R)	(R)	(R)
Share Capital:			
Share Capital	74,600,300.00	74,600,300.00	74,600,300.00
Other Reserves			
Investment Reserve			
Capital Reserve	871,230,628.64	854,317,490.93	834,138,174.86
Loan to T			23,311,143.84
Other Reserves			
Share Reserve	38,399,577.13	38,399,577.13	36,593,228.71
Reserve	241,903,691.18	214,974,182.62	198,717,046.87
Total Share Capital	1,226,134,196.95	1,182,291,550.68	1,120,737,606.60
Total Liability and HOLDERS' EQUITY	1,927,425,201.96	1,762,326,156.96	1,569,621,678.05

Costs of the 2022 FFA World Ag Expo (A) (RMB ¥)

It	N	V	A	tf	h	A
						(R)
I. ρ t						
I : R	(XXXVII)		1,484,903,042.25			1,297,430,369.83
I			1,484,903,042.25			1,297,430,369.83
P						
F						
II. ρ t						
I : C	(XXXVII)		1,435,161,133.62			1,226,514,555.85
I			1,131,971,942.77			968,432,455.76
F						
S						
N						
N						
I						
R						
T	(XXXVIII)		4,960,285.79			5,754,219.28
S	(XXXIX)		15,004,027.73			10,335,392.65
G	(XL)		205,887,172.40			176,371,888.82
R	(XLI)		33,027,987.79			27,962,173.39
F	(XLII)		44,309,717.14			37,658,425.95
I : I			45,149,998.30			36,267,756.91
I			2,761,765.05			1,691,366.88
A : O	(XLIII)		14,907,710.81			13,619,635.06
I	(XLIV)		2,850,458.27			6,937,845.27
I			-15,926,847.45			-6,565,719.92
D						
F						
G						
G						
C	(XLV)		-15,977,325.91			9,417,390.73
A	(XLVI)		-25,191,541.19			-2,140,196.45
A	(XLVII)		-10,345,460.56			-6,179,290.37
G	(XLVIII)		406,184.95			-79,403.55
III. O t						
A : N	(XLIX)		16,391,935.00			92,491,794.67
L : N	(L)		8,553,977.86			11,835,931.80
L : N			9,341,038.73			8,636,583.42
I. ρ t						
L : I	(LI)		15,604,874.13			95,691,143.05
L : I			26,573,712.49			54,830,913.00

Continued
For the year ended December 31, 2022
(All amounts in RMB Yuan)

Item Non-Variable Assets
(RMB Yuan)

Net Profit (Loss) 135,825

附注三 合并现金流量表
 2022年度
 (单位:人民币元)

项目	附注	2022年度	2021年度
一、经营活动产生的现金流量		343,141,450.63	369,798,306.12
销售商品、提供劳务收到的现金	(IV)	265,024,147.50	271,489,388.70
收到的税费返还		154,333.60	3,013,304.93
收到其他与经营活动有关的现金		1,692,773.94	3,068,742.71
购买商品、接受劳务支付的现金		82,345,368.26	70,825,757.20
支付给职工以及为职工支付的现金		18,899,109.47	16,486,961.41
支付的各项税费		16,480,521.45	5,650,976.01
支付其他与经营活动有关的现金		26,568,676.00	19,722,968.32
经营活动产生的现金流量净额		11,229,395.04	14,521,251.32
二、投资活动产生的现金流量		6,245,933.48	5,326,738.38
收回投资收到的现金	(V)	49,902,280.65	4,923,377.54
取得投资收益收到的现金			
处置固定资产、无形资产和其他长期资产收回的现金净额		-5,377,605.11	-3,485,811.81
处置子公司及其他营业单位收到的现金净额			
收到其他与投资活动有关的现金			
投资活动产生的现金流量净额		-2,695,422.53	8,407,356.31

It is not clear whether the N^{+} XVI Ly α emission is produced in the same region as the Ly α emission from the N^{+} V Ly α emission. The Ly α emission from the N^{+} V Ly α emission is produced in the same region as the Ly α emission from the N^{+} V Ly α emission. The Ly α emission from the N^{+} V Ly α emission is produced in the same region as the Ly α emission from the N^{+} V Ly α emission.

. Ob		h		, t f t	
(I) O					
1. C					
2. O					
3. C					
4. C					
(II) O					
1. O					
2. C					
3. A					
4. C					
5. R					
6. E					
7. O					
I. t		h			
				26,929,508.56	
				18,063,484.17	

(I) B (RMB 100)

(II) D (RMB 100)

L ♣ ♠ ♡ : P ♣ ♣ ♣ : H ♣ ♣ ♣ :

GUAN W JIN H WANG M

C F 2022 C h E t t t

I		N	V	A , t f h	A
I. C h f f t t t					
G				1,452,028,763.13	1,211,114,150.81
N					
N					
N					

C 2022
 (A RMB Y)

It	N	V	A	A
II. C h f f t t t				
G			1,650,804.41	52,119,175.58
G				7,777,189.35
N			24,100,366.61	8,755,311.37
N				
G				
-t t f h f f t t t			25,751,171.02	68,651,676.30
G			236,910,178.88	178,536,614.68
G				48,600,000.00
N			53,685,701.28	80,564,032.90
N			8,770,704.43	
G		(LIV)		
-t t f h f f t t t			299,366,584.59	307,700,647.58
N t h f f t t t			-273,615,413.57	-239,048,971.28
III. C h f f f t t			9,153,084.38	2,900,000.00
G				
I : G			9,153,084.38	2,900,000.00
G			387,500,000.00	550,250,000.00
G			151,420,250.00	
G		(LIV)		
-t t f h f f f t t			548,073,334.38	553,150,000.00
G			324,220,000.00	428,342,970.00
G			51,554,507.56	30,297,107.09
I : G				
G			56,121,295.37	60,676,565.61
G		(LIV)		
-t t f h f f f t t			431,895,802.93	519,316,642.70
N t h f f f t t			116,177,531.45	33,833,357.30
I . Eff t f f h t h h h			78,462.87	-38,704.15
. N t h h t			69,861,145.20	-11,357,819.65
A : G			188,734,845.77	200,092,665.42
I. C h h t t h f h		(LV)	258,595,990.97	188,734,845.77
T				
L : P : H :				
GUAN W		JIN H		WANG M

Profit Contribution Statement
For the Year 2022
(All amounts in RMB Yuan)

Item	Amount	Amount
I. Contribution before tax		
Operating income	336,363,866.37	367,674,455.38
Operating expenses	495,591,067.36	804,490,679.80
Operating profit	831,954,933.73	1,172,165,135.18
Other income	153,275,777.22	176,137,498.58
Other expenses	147,419,578.70	141,102,134.39
Profit before tax	2,393,183.16	9,767,527.34
Income tax	596,762,811.79	710,127,325.96
Profit after tax	899,851,350.87	1,037,134,486.27
Net profit	-67,896,417.14	135,030,648.91
II. Contribution after tax		
Operating income	12,396,717.38	
Operating expenses	2,298,348.18	7,089,189.35
Net profit	32,054.56	37,820.00
Income tax		
Profit after tax	14,727,120.12	7,127,009.35
Other income	14,643,564.50	37,662,933.95
Other expenses	54,309,855.16	212,313,500.00
Net profit	68,953,419.66	249,976,433.95
Net profit	-54,226,299.54	-242,849,424.60

It	N	A , t f b t	A V
III. C h f . f . f . . . t t .			
Ga V			
Ga V		334,500,000.00	518,050,000.00
Ga V		120,000,000.00	
. - t t . f . h . f . . ff . . . t t .		454,500,000.00	518,050,000.00
Ga		306,750,000.00	411,050,000.00
Ga			
		26,512,297.06	19,663,754.20
Ga		6,421,875.00	
. - t t . f . h . f . . ff . . . t t .		339,684,172.06	430,713,754.20
N t h f . f . f . . . t t .		114,815,827.94	87,336,245.80
I . Eff t ff h . . . t h h . . . h			
. . . . t		78,462.87	-38,704.15
. N t h . . . h . . . t		-7,228,425.87	-20,521,234.04
A : Ga Va . .		97,615,570.76	118,136,804.80
I. C h . . . h . . . t t h . . . f h . . .		90,387,144.89	97,615,570.76

T

L ♣ ♠ ♡ : P ♣ ♣ ♣ : H ♣ ♣ ♣ :

GUAN W JIN H WANG M

Copyright © 2022
(All rights reserved)

[illegible]

[illegible]

WenZhou KangNing Hospital Co., Ltd. 2022 Annual Report
F 2022
(A RMB Y)

	A		B		C		D		E		F		G		H		I		J		K		L		M		N		O		P		Q		R		S		T		U		V		W		X		Y		Z		AA		AB		AC		AD		AE		AF		AG		AH		AI		AJ		AK		AL		AM		AN		AO		AP		AQ		AR		AS		AT		AU		AV		AW		AX		AY		AZ		BA		BB		BC		BD		BE		BF		BG		BH		BI		BJ		BK		BL		BM		BN		BO		BP		BQ		BR		BS		BT		BU		BV		BW		BX		BY		BZ		CA		CB		CC		CD		CE		CF		CG		CH		CI		CJ		CK		CL		CM		CN		CO		CP		CQ		CR		CS		CT		CU		CV		CW		CX		CY		CZ		DA		DB		DC		DD		DE		DF		DG		DH		DI		DJ		DK		DL		DM		DN		DO		DP		DQ		DR		DS		DT		DU		DV		DW		DX		DY		DZ		EA		EB		EC		ED		EE		EF		EG		EH		EI		EJ		EK		EL		EM		EN		EO		EP		EQ		ER		ES		ET		EU		EV		EW		EX		EY		EZ		FA		FB		FC		FD		FE		FF		FG		FH		FI		FJ		FK		FL		FM		FN		FO		FP		FQ		FR		FS		FT		FU		FV		FW		FX		FY		FZ		GA		GB		GC		GD		GE		GF		GG		GH		GI		GJ		GK		GL		GM		GN		GO		GP		GQ		GR		GS		GT		GU		GV		GW		GX		GY		GZ		HA		HB		HC		HD		HE		HF		HG		HH		HI		HJ		HK		HL		HM		HN		HO		HP		HQ		HR		HS		HT		HU		HV		HW		HX		HY		HZ		IA		IB		IC		ID		IE		IF		IG		IH		II		IJ		IK		IL		IM		IN		IO		IP		IQ		IR		IS		IT		IU		IV		IW		IX		IY		IZ		JA		JB		JC		JD		JE		JF		JG		JH		JI		JJ		JK		JL		JM		JN		JO		JP		JQ		JR		JS		JT		JU		JV		JW		JX		JY		JZ		KA		KB		KC		KD		KE		KF		KG		KH		KI		KJ		KK		KL		KM		KN		KO		KP		KQ		KR		KS		KT		KU		KV		KW		KX		KY		KZ		LA		LB		LC		LD		LE		LF		LG		LH		LI		LJ		LK		LM		LN		LO		LP		LQ		LR		LS		LT		LU		LV		LW		LX		LY		LZ		MA		MB		MC		MD		ME		MF		MG		MH		MI		MJ		MK		ML		MM		MN		MO		MP		MQ		MR		MS		MT		MU		MV		MW		MX		MY		MZ		NA		NB		NC		ND		NE		NF		NG		NH		NI		NJ		NK		NL		NM		NN		NO		NP		NQ		NR		NS		NT		NU		NV		NW		NX		NY		NZ		OA		OB		OC		OD		OE		OF		OG		OH		OI		OJ		OK		OL		OM		ON		OO		OP		OQ		OR		OS		OT		OU		OV		OW		OX		OY		OZ		PA		PB		PC		PD		PE		PF		PG		PH		PI		PJ		PK		PL		PM		PN		PO		PP		PQ		PR		PS		PT		PU		PV		PW		PX		PY		PZ		QA		QB		QC		QD		QE		QF		QG		QH		QI		QJ		QK		QL		QM		QN		QO		QP		QQ		QR		QS		QT		QU		QV		QW		QX		QY		QZ		RA		RB		RC		RD		RE		RF		RG		RH		RI		RJ		RK		RL		RM		RN		RO		RP		RQ		RR		RS		RT		RU		RV		RW		RX		RY		RZ		SA		SB		SC		SD		SE		SF		SG		SH		SI		SJ		SK		SL	
--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	---	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--

WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT
F
(A
RMB Y
)

I	0	P	P	O	Q	T	L	S	S	R	T
I. B	74,600,300.00				834,138,174.86	23,311,143.84		36,593,228.71	193,286,602.86	1,115,307,162.39	
P : C									5,430,444.01	5,430,444.01	
C											
O											
II. B	74,600,300.00				834,138,174.86	23,311,143.84		36,593,228.71	198,717,046.87	1,120,737,606.60	
III. I					20,179,316.07	-23,311,143.84		1,806,348.42	16,257,135.75	61,533,944.08	
(I) T					20,182,750.66				18,063,484.17	18,063,484.17	
(II) O					2,445,056.34				20,182,750.66	20,182,750.66	
1. C										2,445,056.34	
2. C											
3. A					17,737,694.32					17,737,694.32	
4. O											
(III) D											
1. W									-1,806,348.42	-1,806,348.42	
2. P									1,806,348.42	1,806,348.42	
3. O											
(IV) I											
1. C											
2. C											
3. S											
4. C											
5. C											
6. O											
(V) S											
1. W											
2. U											
(VI) O					-3,434.59	-23,311,143.84				23,307,709.25	
I. B	74,600,300.00				834,137,490.93			38,399,577.13	214,974,182.62	1,182,291,550.68	

T
L
GUAN W
P
JIN H
H
WANG M
:

North China Electric Power Group Corporation Limited

F 2022
(A RMB Y)

I. G

(I) C

W K H C ., L . (C)
W C K P R H (温州市康宁精神康复医院)
PRC F 1996. T C

Notes to the Financial Statements
F 2022
(A RMB Y)

II. Basic Information

(I) Basic Information

The Company is a public company listed on the Shanghai Stock Exchange. The Company's registered capital is RMB 100,000,000.00. The Company's fiscal year is from January 1 to December 31. The Company's accounting policy is in accordance with the Accounting Standards for Enterprises. The Company's accounting period is from January 1 to December 31. The Company's accounting currency is RMB. The Company's accounting method is in accordance with the Accounting Standards for Enterprises. The Company's accounting policy is in accordance with the Accounting Standards for Enterprises. The Company's accounting period is from January 1 to December 31. The Company's accounting currency is RMB. The Company's accounting method is in accordance with the Accounting Standards for Enterprises.

(II) General Information

The Company is a public company listed on the Shanghai Stock Exchange.

III. Significant Accounting Policies and Accounting Estimates

1. The Company's accounting policy is in accordance with the Accounting Standards for Enterprises.
2. The Company's accounting period is from January 1 to December 31.
3. The Company's accounting currency is RMB.

Notes to Financial Statements
F 2022
(A RMB Y)

III. S ()

(I) A , t f b b A , t t f B E t
T A S B E
M F , 31, 2022 2022.
C D

(II) A , t
T C 1 J 31 D .

(III) O t
T C 12 .

(I)
T C R (RMB) T C
C PRC RMB. T RMB.
RMB.

() A , t t t f , t , t ,
B : T ,
(T
() . I
, ,

T

Not the Father of the Nation

F 2022
(A RMB Y)

III. S

(I) P t f t f t t t (. t , . . .)

2. $C \rightarrow (\quad)$

T

(1) I  

D R P , C , R P ;

[illegible]

Net Profit attributable to the Company's shareholders
F 2022
(A RMB Y)

III. S ()

(I) P. f. f. t t (t,)

2. C ()

(1) I ()

W C ,
-
W
.

(2) D

① G

W C ,
C . T
.
O
.



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

Wen Zhou Kang Ning Hospital Co., Ltd.
F
(A) 2022
RMB Y)



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

Wen Zhou Kang Ning Hospital Co., Ltd.
F
(A) 2022
RMB Y)

Notes to the Financial Statements
F 2022
(A RMB Y)

III. S ()

() F ()

1. C ()

North E
F 2022
(A RMB Y)

Net Profit attributable to the Company's shareholders
F 2022
(A RMB Y)

III. S ()

() F ()

2. R ()

(3) F ()

F ()
 , ,
 . T
 . T

A ,

Notes to Financial Statements
F 2022
(A RMB Y)

III. S ()

() F ()

2. R ()

(6) F

F - , ,
 , - ,
 , ,
 .

D ,

A ,

3. D

W , C :

— T ;

— T , ;

— T , C

A ,

I ,

N t t h F		t t t	
F	2022		
(A	RMB Y	)	
III. S			()

三、非经常性损益对公司净利润的影响

2022年度非经常性损益对公司净利润的影响如下表所示：

III. S 非经常性损益对公司净利润的影响 (单位：人民币元)

() F 非经常性损益对公司净利润的影响 (单位：人民币元)

4. D 非经常性损益对公司净利润的影响 (单位：人民币元)

W 非经常性损益对公司净利润的影响 (单位：人民币元)

W 非经常性损益对公司净利润的影响 (单位：人民币元)

W C 非经常性损益对公司净利润的影响 (单位：人民币元)

5. D 非经常性损益对公司净利润的影响 (单位：人民币元)

T 非经常性损益对公司净利润的影响 (单位：人民币元)

6. T 非经常性损益对公司净利润的影响 (单位：人民币元)

T C 非经常性损益对公司净利润的影响 (单位：人民币元)

G 非经常性损益对公司净利润的影响 (单位：人民币元)

F B E N .14 - R (2017), A S

North E
F 2022
(A RMB Y)

Notes to Financial Statements

F 2022
(A RMB Y)

III. S ()

(I)I

1. C
I
I . C ,
.
2. V
I
3. B
A ,
N
N , - ,

Notes to the Financial Statements

F 2022
(A RMB Y)

III. S ()

(I) I ()

4. I
A

5. A
T -

(II) C t t t

1. R
T C . T C
. C
. T C
()

2. D
F



Net Profit attributable to the Company's shareholders
F 2022
(A RMB Y)

III. S ()

(III) L -t , ty t t (t ,)

2. D v

Notes to Financial Statements

F 2022
(A RMB Y)

III. S ()

(III) L -t , ty t t (t ,)

3. S

(1) L -

L - C
- - . E
C

(2) L -

L - . W G
,
G , . W

T C
- . T
- . I
(O C O , E)
, -

T C , O C
O , E
C

Net Profit attributable to the Company

FY 2022
(A RMB Y)

III. S ()

(III) L -t , ty t t (t ,)

3. S ()

(2) L - ()

U C C ,
C ,
U ,
.

T C -
C -
C () 0.018 GS0 0.. W 0.5 (8 T

N t t b F

F 2022

(A RMB Y)

III. S

(III) L - t , t t (t ,)

3. S $(\quad)$

(3) D $\rightarrow$ - ()

A 100x100 grid of random characters and symbols. The characters are scattered across the grid, including letters (W, G, E, O, C), punctuation (comma, semicolon, apostrophe, period), and various symbols (clover, arrow, heart, etc.). The distribution is random, with some characters appearing more frequently than others.

Notes to the Financial Statements
F 2022
(A RMB Y)

III. S ()

(I) F

1. R
F
(1)
(2)
T
S
G
A
2. D
F
T
F
W

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

III. Significant accounting estimates and assumptions

(I) Financial instruments

2. Derivatives

The Company has not entered into any derivatives contracts for hedging or other purposes.

Contract type	Derivative instrument	Notional amount (RMB Yuan)			Average interest rate (%)
		Notional amount	Notional amount	Notional amount	
Bank deposits	Savings	-	35	5	2.71
Bank deposits	Savings	-	3-10	0-5	9.50-33.33
Bank deposits	Savings	-	4-10	5	9.50-23.75
Bank deposits	Savings	-	3-10	0-5	9.50-33.33

3. Derivatives

The Company has not entered into any derivatives contracts for hedging or other purposes.

(II) Contractual obligations

The Company has no contractual obligations that are not reflected in the financial statements.

Net Profit

FY 2022
(A RMB Y)

III. S ()

(I) B

1. R

T C
;

A
.

2. G

G
.

G

(1) A
;

(2) B

(3) T
.

G
.

3. G

I
;
3
;
B
.

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(I) Basic accounting policies

4. Measurement basis

The Company uses the historical cost measurement basis for assets and liabilities. For non-current assets and liabilities that are measured at fair value, the Company uses the fair value measurement basis. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets.

The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets.

The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets.

(II) Important accounting policies

1. Valuation basis

(1) Initial recognition and measurement

The Company uses the historical cost measurement basis for assets and liabilities. For non-current assets and liabilities that are measured at fair value, the Company uses the fair value measurement basis. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets.

(2) Subsequent measurement

The Company uses the historical cost measurement basis for assets and liabilities. For non-current assets and liabilities that are measured at fair value, the Company uses the fair value measurement basis. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets.

The Company uses the historical cost measurement basis for assets and liabilities. For non-current assets and liabilities that are measured at fair value, the Company uses the fair value measurement basis. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets. The fair value measurement basis is used for the following items: financial assets and liabilities, investment properties, and biological assets.

Notes to Financial Statements
F 2022
(A RMB Y)

III. S ()

(II) I t (t ,)

2. E

E t t

f

It	(y)	A t t b	B
I	40-50	S -	S
S	5	S -	E
C	20-30	S -	E
M	5-20	S -	E
T	10	S -	E

3. S

E C

R : R

D : D

Ninth Edition


F 2022
(A RMB Y)

III. S $\rightarrow$ $\mu\mu$ $\rightarrow$ $\mu\mu$ $\rightarrow$ $\mu\mu$ ()

$$(II) \quad I_t \dots t \quad (t, \dots)$$
[illegible]

(1) I       ;

(2) T C ;

(3) T 

(4) T C $\begin{matrix} \bullet & \bullet & \bullet \\ \diagdown & \diagup & \diagdown \end{matrix}$, $\begin{matrix} \bullet & \bullet & \bullet \\ \diagup & \diagdown & \diagup \end{matrix}$, $\begin{matrix} \bullet & \bullet & \bullet \\ \diagdown & \diagup & \diagdown \end{matrix}$, $\begin{matrix} \bullet & \bullet & \bullet \\ \diagup & \diagdown & \diagup \end{matrix}$, $\begin{matrix} \bullet & \bullet & \bullet \\ \diagdown & \diagup & \diagdown \end{matrix}$, $\begin{matrix} \bullet & \bullet & \bullet \\ \diagup & \diagdown & \diagup \end{matrix}$, $\begin{matrix} \bullet & \bullet & \bullet \\ \diagdown & \diagup & \diagdown \end{matrix}$, $\begin{matrix} \bullet & \bullet & \bullet \\ \diagup & \diagdown & \diagup \end{matrix}$;

(5) $T \rightarrow \mathbb{A}^1$ is a $\mathbb{G}_m$ -torsor.

I $\frac{1}{2}$ $\frac{1}{3}$ $\frac{1}{6}$ $\frac{1}{9}$ $\frac{1}{18}$ $\frac{1}{27}$ $\frac{1}{54}$,

(III) I $t f - t t$

L' - , - ,
 . I
 ,
 . T
 . P
 . I
 . A

III. S


(III) I $t f - t$ $t (t ,)$

G

W C  , C  ,  . T 

O    ,  .

(I) L -t

L - 

() C t t L t

三、非经常性损益对公司净利润的影响

2022年度非经常性损益对公司净利润的影响如下表所示：

III. 非经常性损益对公司净利润的影响 (单位：人民币元)

(一) 非经常性损益明细表

1. 非经常性损益明细表
2. 非经常性损益对公司净利润的影响

Notes to Financial Statements

F 2022
(A RMB Y)

III. Significant Accounting Policies and Accounting Estimates

(I) Basic Accounting Policies

2. Accounting Basis

(2) Depreciation

T C E A W U M . T

T , . I , C

A ,

T . C . U ,

U ,

3. A W C () : C ; C

Notes to the Financial Statements
F 2022
(A RMB Y)

III. S ()

(II) P.

T C ,

(1) C

(2) C

(3)

A

F ,

W ,

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

III. Significant accounting policies and accounting estimates

(III) Intangible assets

According to the Company's business characteristics and the nature of its intangible assets, the Company's intangible assets are divided into identifiable intangible assets and non-identifiable intangible assets. Identifiable intangible assets are further divided into finite-lived intangible assets and indefinite-lived intangible assets. The Company's finite-lived intangible assets are amortized on a straight-line basis over their estimated useful lives. The Company's indefinite-lived intangible assets are not amortized.

1. Goodwill

Goodwill is the difference between the purchase price and the fair value of the identifiable intangible assets acquired in a business combination. Goodwill is measured at the acquisition date and is not subject to amortization. Goodwill is tested for impairment annually or more frequently if there are indicators of impairment. If the carrying amount of goodwill exceeds its recoverable amount, the excess is recognized as an impairment loss. Goodwill is measured at the acquisition date and is not subject to amortization. Goodwill is tested for impairment annually or more frequently if there are indicators of impairment. If the carrying amount of goodwill exceeds its recoverable amount, the excess is recognized as an impairment loss.

Goodwill is measured at the acquisition date and is not subject to amortization. Goodwill is tested for impairment annually or more frequently if there are indicators of impairment. If the carrying amount of goodwill exceeds its recoverable amount, the excess is recognized as an impairment loss.

Goodwill is measured at the acquisition date and is not subject to amortization. Goodwill is tested for impairment annually or more frequently if there are indicators of impairment. If the carrying amount of goodwill exceeds its recoverable amount, the excess is recognized as an impairment loss.

Net Profit attributable to the Company's Shareholders

FY 2022
(Amount in RMB Yuan)

III. Significant changes in the Company's net profit attributable to the Company's share-
holders (Amount in RMB Yuan)

(III) Changes in net profit attributable to the Company's share-
holders (Amount in RMB Yuan)

2. Changes in net profit attributable to the Company's share-
holders (Amount in RMB Yuan)

As of the end of the reporting period, the Company's net profit attributable to the Company's share-
holders was RMB 10,000,000.00, which was an increase of RMB 10,000,000.00 compared with the
beginning of the reporting period. The main reasons for the increase are as follows:
1. The Company's operating income increased significantly due to the expansion of its business scale and
the improvement of its operating efficiency.
2. The Company's operating expenses decreased significantly due to the optimization of its cost structure
and the improvement of its cost control.
3. The Company's non-operating income increased significantly due to the increase in its non-operating
income.

I. Changes in net profit attributable to the Company's share-
holders (Amount in RMB Yuan)
O (Amount in RMB Yuan)
(), C (Amount in RMB Yuan)
A (Amount in RMB Yuan)
I (Amount in RMB Yuan)
C (Amount in RMB Yuan)

(I) Changes in net profit attributable to the Company's share-
holders (Amount in RMB Yuan)

1. A (Amount in RMB Yuan)
T C (Amount in RMB Yuan)
C (Amount in RMB Yuan)

I (Amount in RMB Yuan)
C (Amount in RMB Yuan)

Notes to Financial Statements

F 2022
(A RMB Y)

III. Significant accounting policies and accounting estimates

(I) Significant accounting policies

1. Assets and liabilities classification

The Company classifies assets and liabilities based on their nature, and the classification is as follows:

Assets: Assets are classified into current assets and non-current assets. Current assets are those assets that are expected to be realized or consumed within one year or the operating cycle of the Company. Non-current assets are those assets that are not expected to be realized or consumed within one year or the operating cycle of the Company.

Liabilities: Liabilities are classified into current liabilities and non-current liabilities. Current liabilities are those liabilities that are expected to be settled within one year or the operating cycle of the Company. Non-current liabilities are those liabilities that are not expected to be settled within one year or the operating cycle of the Company.

Warrantable assets: Warrantable assets are those assets that are expected to be realized or consumed within one year or the operating cycle of the Company, and are classified as current assets.

- **Assets:** Assets are classified into current assets and non-current assets. Current assets are those assets that are expected to be realized or consumed within one year or the operating cycle of the Company. Non-current assets are those assets that are not expected to be realized or consumed within one year or the operating cycle of the Company.
- **Liabilities:** Liabilities are classified into current liabilities and non-current liabilities. Current liabilities are those liabilities that are expected to be settled within one year or the operating cycle of the Company. Non-current liabilities are those liabilities that are not expected to be settled within one year or the operating cycle of the Company.
- **Warrantable assets:** Warrantable assets are those assets that are expected to be realized or consumed within one year or the operating cycle of the Company, and are classified as current assets.

Warrantable assets: Warrantable assets are those assets that are expected to be realized or consumed within one year or the operating cycle of the Company, and are classified as current assets.

Liabilities: Liabilities are classified into current liabilities and non-current liabilities. Current liabilities are those liabilities that are expected to be settled within one year or the operating cycle of the Company. Non-current liabilities are those liabilities that are not expected to be settled within one year or the operating cycle of the Company.

Notes to the Financial Statements

F 2022
(A RMB Y)

III. Significant accounting policies and accounting estimates

(I) Significant accounting policies

1. Assets and liabilities classification

F , C , I . I , C :

- C , , ,

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Classification of assets and liabilities

I. Assets and liabilities are classified as current assets and current liabilities based on whether they are expected to be realized or settled within one year (or within one normal business cycle) from the reporting date.

A. Assets and liabilities that are not expected to be realized or settled within one year (or within one normal business cycle) from the reporting date are classified as non-current assets and non-current liabilities.

F. Assets and liabilities are classified as current assets and current liabilities based on whether they are expected to be realized or settled within one year (or within one normal business cycle) from the reporting date.

1. The classification of assets and liabilities as current assets and current liabilities is based on whether they are expected to be realized or settled within one year (or within one normal business cycle) from the reporting date.

2. The classification of assets and liabilities as non-current assets and non-current liabilities is based on whether they are expected to be realized or settled within one year (or within one normal business cycle) from the reporting date.

I. Assets and liabilities are classified as current assets and current liabilities based on whether they are expected to be realized or settled within one year (or within one normal business cycle) from the reporting date.

(2) Classification of assets and liabilities

1. Classification of assets and liabilities

G. Assets and liabilities are classified as current assets and current liabilities based on whether they are expected to be realized or settled within one year (or within one normal business cycle) from the reporting date.

G. Assets and liabilities are classified as current assets and current liabilities based on whether they are expected to be realized or settled within one year (or within one normal business cycle) from the reporting date.

2. Classification of assets and liabilities

G. Assets and liabilities are classified as current assets and current liabilities based on whether they are expected to be realized or settled within one year (or within one normal business cycle) from the reporting date.

Net Profit Before Income Tax

FY 2022
(Amount in RMB Yuan)

III. Significant Accounting Policies and Accounting Estimates

(I) Government Grants

3. Accounting Policy for Government Grants

The Company recognizes government grants based on the nature of the grants and the Company's accounting policy. Government grants are divided into two types: government grants related to assets and government grants related to income. Government grants related to assets are recognized as deferred income and amortized over the useful life of the related assets. Government grants related to income are recognized as income when they are received. Government grants related to assets are recognized as income when they are received. Government grants related to income are recognized as income when they are received.

(II) Deferred Income Tax

I. Accounting Policy for Deferred Income Tax

The Company recognizes deferred income tax based on the nature of the deferred income tax. Deferred income tax is recognized as a liability when it is expected to be paid in the future. Deferred income tax is recognized as an asset when it is expected to be received in the future. Deferred income tax is recognized as an asset when it is expected to be received in the future.

D. Accounting Policy for Deferred Income Tax

The Company recognizes deferred income tax based on the nature of the deferred income tax. Deferred income tax is recognized as a liability when it is expected to be paid in the future. Deferred income tax is recognized as an asset when it is expected to be received in the future. Deferred income tax is recognized as an asset when it is expected to be received in the future.

North E
F 2022
(A RMB Y)

Ninth Edition

F 2022
(A RMB Y)

III. S

$$(\quad \text{III} \text{ D } f \quad t \quad t \quad f \quad t \quad t \quad (\quad t \quad , \quad))$$
[illegible]

- W        
- W          

(III) $\mathbf{L}$

A $\frac{1}{2}$, $\frac{1}{2}$, $\frac{1}{2}$. A $\frac{1}{2}$, C $\frac{1}{2}$, $\frac{1}{2}$. A $\frac{1}{2}$, $\frac{1}{2}$, $\frac{1}{2}$. ($\frac{1}{2}$)

F $\rightarrow$ $\frac{1}{2}(\sigma_1 + \sigma_2)$, C $\rightarrow$ $\frac{1}{2}(\sigma_1 - \sigma_2)$, σ_1 $\rightarrow$ $\frac{1}{2}(F + C)$, σ_2 $\rightarrow$ $\frac{1}{2}(F - C)$.

I
COVID-19 , , C , - :

- T ;
- A ,

Notes to the Financial Statements

F 2022
(A RMB Y)

III. Significant Accounting Policies and Accounting Estimates

(III) Long-term Assets

1. Intangible Assets

(1) Recognition

A company should recognize an intangible asset when it is probable that the expected future economic benefits that will flow from the asset to the company can be reliably measured. The recognition of an intangible asset should be based on the following conditions:

- The company has control over the intangible asset.
- The intangible asset is identifiable and separable from the company's other assets and liabilities.
- The intangible asset is expected to generate future economic benefits.
- The intangible asset is expected to be used in the company's operations.

The company should recognize an intangible asset when it is probable that the expected future economic benefits that will flow from the asset to the company can be reliably measured. The recognition of an intangible asset should be based on the following conditions:

The company should recognize an intangible asset when it is probable that the expected future economic benefits that will flow from the asset to the company can be reliably measured. The recognition of an intangible asset should be based on the following conditions:

Notes to Financial Statements

F 2022
(A RMB Y)

III. Significant Accounting Policies and Accounting Estimates

(III) Long-term Assets

1. Intangible Assets ()

(2) Intangible Assets

A company's intangible assets are those assets that are identifiable and can be controlled by the company, and whose benefits can be realized in the future. Intangible assets are divided into identifiable intangible assets and non-identifiable intangible assets. Identifiable intangible assets are those intangible assets that can be separated from the company and sold or transferred individually. Non-identifiable intangible assets are those intangible assets that cannot be separated from the company and cannot be sold or transferred individually.

• The company's intangible assets are divided into identifiable intangible assets and non-identifiable intangible assets. Identifiable intangible assets are those intangible assets that can be separated from the company and sold or transferred individually. Non-identifiable intangible assets are those intangible assets that cannot be separated from the company and cannot be sold or transferred individually.

• The company's intangible assets are divided into identifiable intangible assets and non-identifiable intangible assets. Identifiable intangible assets are those intangible assets that can be separated from the company and sold or transferred individually. Non-identifiable intangible assets are those intangible assets that cannot be separated from the company and cannot be sold or transferred individually.

• The company's intangible assets are divided into identifiable intangible assets and non-identifiable intangible assets. Identifiable intangible assets are those intangible assets that can be separated from the company and sold or transferred individually. Non-identifiable intangible assets are those intangible assets that cannot be separated from the company and cannot be sold or transferred individually.

• The company's intangible assets are divided into identifiable intangible assets and non-identifiable intangible assets. Identifiable intangible assets are those intangible assets that can be separated from the company and sold or transferred individually. Non-identifiable intangible assets are those intangible assets that cannot be separated from the company and cannot be sold or transferred individually.

• The company's intangible assets are divided into identifiable intangible assets and non-identifiable intangible assets. Identifiable intangible assets are those intangible assets that can be separated from the company and sold or transferred individually. Non-identifiable intangible assets are those intangible assets that cannot be separated from the company and cannot be sold or transferred individually.

T C 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1985 1984 1983 1982 1981 1980 1979 1978 1977 1976 1975 1974 1973 1972 1971 1970 1969 1968 1967 1966 1965 1964 1963 1962 1961 1960 1959 1958 1957 1956 1955 1954 1953 1952 1951 1950 1949 1948 1947 1946 1945 1944 1943 1942 1941 1940 1939 1938 1937 1936 1935 1934 1933 1932 1931 1930 1929 1928 1927 1926 1925 1924 1923 1922 1921 1920 1919 1918 1917 1916 1915 1914 1913 1912 1911 1910 1909 1908 1907 1906 1905 1904 1903 1902 1901 1900 1899 1898 1897 1896 1895 1894 1893 1892 1891 1890 1889 1888 1887 1886 1885 1884 1883 1882 1881 1880 1879 1878 1877 1876 1875 1874 1873 1872 1871 1870 1869 1868 1867 1866 1865 1864 1863 1862 1861 1860 1859 1858 1857 1856 1855 1854 1853 1852 1851 1850 1849 1848 1847 1846 1845 1844 1843 1842 1841 1840 1839 1838 1837 1836 1835 1834 1833 1832 1831 1830 1829 1828 1827 1826 1825 1824 1823 1822 1821 1820 1819 1818 1817 1816 1815 1814 1813 1812 1811 1810 1809 1808 1807 1806 1805 1804 1803 1802 1801 1800 1799 1798 1797 1796 1795 1794 1793 1792 1791 1790 1789 1788 1787 1786 1785 1784 1783 1782 1781 1780 1779 1778 1777 1776 1775 1774 1773 1772 1771 1770 1769 1768 1767 1766 1765 1764 1763 1762 1761 1760 1759 1758 1757 1756 1755 1754 1753 1752 1751 1750 1749 1748 1747 1746 1745 1744 1743 1742 1741 1740 1739 1738 1737 1736 1735 1734 1733 1732 1731 1730 1729 1728 1727 1726 1725 1724 1723 1722 1721 1720 1719 1718 1717 1716 1715 1714 1713 1712 1711 1710 1709 1708 1707 1706 1705 1704 1703 1702 1701 1700 1699 1698 1697 1696 1695 1694 1693 1692 1691 1690 1689 1688 1687 1686 1685 1684 1683 1682 1681 1680 1679 1678 1677 1676 1675 1674 1673 1672 1671 1670 1669 1668 1667 1666 1665 1664 1663 1662 1661 1660 1659 1658 1657 1656 1655 1654 1653 1652 1651 1650 1649 1648 1647 1646 1645 1644 1643 1642 1641 1640 1639 1638 1637 1636 1635 1634 1633 1632 1631 1630 1629 1628 1627 1626 1625 1624 1623 1622 1621 1620 1619 1618 1617 1616 1615 1614 1613 1612 1611 1610 1609 1608 1607 1606 1605 1604 1603 1602 1601 1600 1599 1598 1597 1596 1595 1594 1593 1592 1591 1590 1589 1588 1587 1586 1585 1584 1583 1582 1581 1580 1579 1578 1577 1576 1575 1574 1573 1572 1571 1570 1569 1568 1567 1566 1565 1564 1563 1562 1561 1560 1559 1558 1557 1556 1555 1554 1553 1552 1551 1550 1549 1548 1547 1546 1545 1544 1543 1542 1541 1540 1539 1538 1537 1536 1535 1534 1533 1532 1531 1530 1529 1528 1527 1526 1525 1524 1523 1522 1521 1520 1519 1518 1517 1516 1515 1514 1513 1512 1511 1510 1509 1508 1507 1506 1505 1504 1503 1502 1501 1500 1499 1498 1497 1496 1495 1494 1493 1492 1491 1490 1489 1488 1487 1486 1485 1484 1483 1482 1481 1480 1479 1478 1477 1476 1475 1474 1473 1472 1471 1470 1469 1468 1467 1466 1465 1464 1463 1462 1461 1460 1459 1458 1457 1456 1455 1454 1453 1452 1451 1450 1449 1448 1447 1446 1445 1444 1443 1442 1441 1440 1439 1438 1437 1436 1435 1434 1433 1432 1431 1430 1429 1428 1427 1426 1425 1424 1423 1422 1421 1420 1419 1418 1417 1416 1415 1414 1413 1412 1411 1410 1409 1408 1407 1406 1405 1404 1403 1402 1401 1400 1399 1398 1397 1396 1395 1394 1393 1392 1391 1390 1389 1388 1387 1386 1385 1384 1383 1382 1381 1380 1379 1378 1377 1376 1375 1374 1373 1372 1371 1370 1369 1368 1367 1366 1365 1364 1363 1362 1361 1360 1359 1358 1357 1356 1355 1354 1353 1352 1351 1350 1349 1348 1347 1346 1345 1344 1343 1342 1341 1340 1339 1338 1337 1336 1335 1334 1333 1332 1331 1330 1329 1328 1327 1326 1325 1324 1323 1322 1321 1320 1319 1318 1317 1316 1315 1314 1313 1312 1311 1310 1309 1308 1307 1306 1305 1304 1303 1302 1301 1300 1299 1298 1297 1296 1295 1294 1293 1292 1291 1290 1289 1288 1287 1286 1285 1284 1283 1282 1281 1280 1279 1278 1277 1276 1275 1274 1273 1272 1271 1270 1269 1268 1267 1266 1265 1264 1263 1262 1261 1260 1259 1258 1257 1256 1255 1254 1253 1252 1251 1250 1249 1248 1247 1246 1245 1244 1243 1242 1241 1240 1239 1238 1237 1236 1235 1234 1233 1232 1231 1230 1229 1228 1227 1226 1225 1224 1223 1222 1221 1220 1219 1218 1217 1216 1215 1214 1213 1212 1211 1210 1209 1208 1207 1206 1205 1204 1203 1202 1201 1200 1199 1198 1197 1196 1195 1194 1193 1192 1191 1190 1189 1188 1187 1186 1185 1184 1183 1182 1181 1180 1179 1178 1177 1176 1175 1174 1173 1172 1171 1170 1169 1168 1167 1166 1165 1164 1163 1162 1161 1160 1159 1158 1157 1156 1155 1154 1153 1152 1151 1150 1149 1148 1147 1146 1145 1144 1143 1142 1141 1140 1139 1138 1137 1136 1135 1134 1133 1132 1131 1130 1129 1128 1127 1126 1125 1124 1123 1122 1121 1120 1119 1118 1117 1116 1115 1114 1113 1112 1111 1110 1109 1108 1107 1106 1105 1104 1103 1102 1101 1100 1099 1098 1097 1096 1095 1094 1093 1092 1091 1090 1089 1088 1087 1086 1085 1084 1083 1082 1081 1080 1079 1078 1077 1076 1075 1074 1073 1072 1071 1070 1069 1068 1067 1066 1065 1064 1063 1062 1061 1060 1059 1058 1057 1056 1055 1054 1053 1052 1051 1050 1049 1048 1047 1046 1045 1044 1043 1042 1041 1040 1039 1038 1037 1036 1035 1034 1033 1032 1031 1030 1029 1028 1027 1026 1025 1024 1023 1022 1021 1020 1019 1018 1017 1016 1015 1014 1013 1012 1011 1010 1009 1008 1007 1006 1005 1004 1003 1002 1001 1000 999 998 997 996 995 994 993 992 991 990 989 988 987 986 985 984 983 982 981 980 979 978 977 976 975 974 973 972 971 970 969 968 967 966 965 964 963 962 961 960 959 958 957 956 955 954 953 952 951 950 949 948 947 946 945 944 943 942 941 940 939 938 937 936 935 934 933 932 931 930 929 928 927 926 925 924 923 922 921 920 919 918 917 916 915 914 913 912 911 910 909 908 907 906 905 904 903 902 901 900 899 898 897 896 895 894 893 892 891 890 889 888 887 886 885 884 883 882 881 880 879 878 877 876 875 874 873 872 871 870 869 868 867 866 865 864 863 862 861 860 859 858 857 856 855 854 853 852 851 850 849 848 847 846 845 844 843 842 841 840 839 838 837 836 835 834 833 832 831 830 829 828 827 826 825 824 823 822 821 820 819 818 817 816 815 814 813 812 811 810 809 808 807 806 805 804 803 802 801 800 799 798 797 796 795 794 793 792 791 790 789 788 787 786 785 784 783 782 781 780 779 778 777 776 775 774 773 772 771 770 769 768 767 766 765 764 763 762 761 760 759 758 757 756 755 754 753 752 751 750 749 748 747 746 745 744 743 742 741 740 739 738 737 736 735 734 733 732 731 730 729 728 727 726 725 724 723 722 721 720 719 718 717 716 715 714 713 712 711 710 709 708 707 706 705 704 703 702 701 700 699 698 697 696 695 694 693 692 691 690 689 688 687 686 685 684 683 682 681 680 679 678 677 676 675 674 673 672 671 670 669 668 667 666 665 664 663 662 661 660 659 658 657 656 655 654 653 652 651 650 649 648 647 646 645 644 643 642 641 640 639 638 637 636 635 634 633 632 631 630 629 628 627 626 625 624 623 622 621 620 619 618 617 616 615 614 613 612 611 610 609 608 607 606 605 604 603 602 601 600 599 598 597 596 595 594 593 592 591 590 589 588 587 586 585 584 583 582 581 580 579 578 577 576 575 574 573 572 571 570 569 568 567 566 565 564 563 562 561 560 559 558 557 556 555 554 553 552 551 550 549 548 547 546 545 544 543 542 541 540 539 538 537 536 535 534 533 532 531 530 529 528 527 526 525 524 523 522 521 520 519 518 517 516 515 514 513 512 511 510 509 508 507 506 505 504 503 502 501 500 499 498 497 496 495 494 493 492 491 490 489 488 487 486 485 484 483 482 481 480 479 478 477 476 475 474 473 472 471 470 469 468 467 466 465 464 463 462 461 460 459 458 457 456 455 454 453 452 451 450 449 448 447 446 445 444 443 442 441 440 439 438 437 436 435 434 433 432 431 430 429 428 427 426 425 424 423 422 421 420 419 418 417 416 415 414 413 412 411 410 409 408 407 406 405 404 403 402 401 400 399 398 397 396 395 394 393 392 391 390 389 388 387 386 385 384 383 382 381 380 379 378 377 376 375 374 373 372 371 370 369 368 367 366 365 364 363 362 361 360 359 358 357 356 355 354 353 352 351 350 349 348 347 346 345 344 343 342 341 340 339 338 337 336 335 334 333 332 331 330 329 328 327 326 325 324 323 322 321 320 319 318 317 316 315 314 313 312 311 310 309 308 307 306 305 304 303 302 301 300 299 298 297 296 295 294 293 292 291 290 289 288 287 286 285 284 283 282 281 280 279 278 277 276 275 274 273 272 271 270 269 268 267 266 265 264 263 262 261 260 259 258 257 256 255 254 253 252 251 250 249 248 247 246 245 244 243 242 241 240 239 238 237 236 235 234 233 232 231 230 229 228 227 226 225 224 223 222 221 220 219 218 217 216 215 214 213 212 211 210 209 208 207 206 205 204 203 202 201 200 199 198 197 196 195 194 193 192 191 190 189 188 187 186 185 184 183 182 181 180 179 178 177 176 175 174 173 172 171 170 169 168 167 166 165 164 163 162 161 160 159 158 157 156 155 154 153 152 151 150 149 148 147 146 145 144 143 142 141 140 139 138 137 136 135 134 133 132 131 130 129 128 127 126 125 124 123 122 121 120 119 118 117 116 115 114 113 112 111 110 109 108 107 106 105 104 103 102 101 100 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 82 81 80 79 78 77 76 75 74 73 72 71 70 69 68 67 66 65 64 63 62 61 60 59 58 57 56 55 54 53 52 51 50 49 48 47 46 45 44 43 42 41 40 39 38 37 36 35 34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

Value of the intangible assets is determined by the company's management. The company's management has determined the value of the intangible assets based on the company's management's judgment.

Net Profit attributable to the Company's shareholders
F 2022
(A RMB Y)

III. S ()

(III) L ()

1. T C ()

(2) L ()

A , , C

A

Notes to the Financial Statements

F 2022
(A RMB Y)

III. Significant accounting policies and accounting estimates

(III) Long-term assets

1. Intangible assets

(4) Land use rights

T C :
:

- : ;
- : .

I , C , - ,
 ,
 .

I , C ,
 - - ,
 . F
 , C
 - -

(5) Research and development expenses of COVID-19 vaccine

F COVID-19 , C ,
 ,
 . I
 , C , W
 ,
 - ,
 , C

Notes to Financial Statements

F 2022
(A RMB Y)

III. Significant Accounting Policies and Accounting Estimates

(III) L (t ,)

1. T C ()

(5) R COVID-19 ()

F - , C . I
 , C ;
 , C

2. T C

A , C
 . A ,
 ()0.5 ()0.366.5 ()0.5 ()0.5 ()0.5

N t t h F		t t t	
F	2022		
(A	RMB Y	)	
III. S			()
(III)			

F 2022
(A RMB Y)

III. S

(III) L (t ,)

2. $T \subset C$ ()

(3) R $\rightarrow$ COVID-19

- F
COVID-19 , C . I ,
C ; C ,
F
COVID-19 , C . I
C W , -

Net Profit 2022
(A RMB Y)

III. S ()

(III) L (t ,)

3. S ()

(2) T C

I - C 2. T
C ; - ,
C , ,
F ,
N III (X) F .

(I) t

T C , ,

A C : (1)
C ; (2)
C ; (3)
C T

() f t t t

T C ,

1. E

A N III. (XXIV), C
T

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Basis of preparation: The financial statements are prepared on the basis of historical cost.

2. Basis of consolidation

A consolidated financial statement is prepared by the Company and its subsidiaries. The consolidation is based on the control principle. The Company's financial statements are consolidated with the financial statements of its subsidiaries. The consolidation is based on the control principle. The Company's financial statements are consolidated with the financial statements of its subsidiaries.

The Company's financial statements are consolidated with the financial statements of its subsidiaries. The consolidation is based on the control principle. The Company's financial statements are consolidated with the financial statements of its subsidiaries. The consolidation is based on the control principle. The Company's financial statements are consolidated with the financial statements of its subsidiaries.

3. Basis of consolidation

The Company's financial statements are consolidated with the financial statements of its subsidiaries. The consolidation is based on the control principle. The Company's financial statements are consolidated with the financial statements of its subsidiaries. The consolidation is based on the control principle. The Company's financial statements are consolidated with the financial statements of its subsidiaries.

4. Basis of consolidation

The Company's financial statements are consolidated with the financial statements of its subsidiaries. The consolidation is based on the control principle. The Company's financial statements are consolidated with the financial statements of its subsidiaries. The consolidation is based on the control principle. The Company's financial statements are consolidated with the financial statements of its subsidiaries.

Item	End of period	Percentage
Assets	180	
Liabilities	570	
Net assets	10.79%	
Gross profit	60	
Diluted EPS	14.00%	
Prior year	2.50%	

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(I) Cash and Cash Equivalents
In 2021, the Company's cash and cash equivalents were RMB 15,123,456.78. In 2022, the Company's cash and cash equivalents were RMB 16,789,012.34. The Company's cash and cash equivalents are classified into three categories: restricted cash, cash, and cash equivalents. The Company's cash and cash equivalents are measured at fair value. The Company's cash and cash equivalents are classified into three categories: restricted cash, cash, and cash equivalents. The Company's cash and cash equivalents are measured at fair value.

IV. Tax

(I) Main Tax Types and Rates		
VAT (Value Added Tax)	Tax Rate	3%, 6%, 13%
Corporate Income Tax	Tax Rate	25%
Urban Maintenance and Construction Tax	Tax Rate	7%
Education Fee附加	Tax Rate	5%
Local Education Fee附加	Tax Rate	15%, 20%, 25%
City Maintenance and Construction Tax	Tax Rate	
Tax Incentives		
Wuxi Kangning Hospital Co., Ltd.		15%
Zhejiang Hantong Hospital Co., Ltd.		15%
Yunnan Hantong Medical Co., Ltd.		20%

Notes to Financial Statements
F 2022
(A RMB Y)

IV. Taxes ()

(II) Profit tax

1. Profit tax
L VAT P B T (C S [2016] N . 36) M F
S T A , C
A M M I (O S C N . 149)
S C I M A M I
(O M H N . 35) M H

Notes to the Financial Statements		WenZhou Kangning Hospital Co., Ltd.	
F 2022		t t t	
(A RMB Y)		)	
V. N		)	
(I) C h t h			
		B t h	B))
		f h	
I			)
C)		454,907.26	971,773.72

五、非经常性损益对公司净利润的影响

五、非经常性损益对公司净利润的影响

(三) 非经常性损益

1. 非经常性损益

A	B		C
	非经常性损益	非经常性损益	
W	388,961,193.05	303,910,574.15	
1-2	4,755,919.87	9,812,859.20	
2-3	3,941,367.25	4,259,870.27	
Q	5,180,894.08	3,140,407.07	
S	402,839,374.25	321,123,710.69	
L	20,002,683.36	9,365,835.23	
T	382,836,690.89	311,757,875.46	

T 非经常性损益 C 非经常性损益

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) A ()

2. A										
	B		B		B		B		B	
	P		P		P		P		P	
	P		P		P		P		P	
C t y	A , t	(%)	A , t	(%)	B ,	A	(%)	A	(%)	B
P										
	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61	2.26	4,590,286.39	63.33	2,657,692.22
I										
M	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61	50.00	4,590,286.39	63.33	2,657,692.22
P										
	384,617,398.37	95.48	7,488,540.70							

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) A ()

2. A ()
P :

It	B	B		P	P	f
		f				
		t		t		f (%)
M		18,221,975.88	12,514,142.66			68.68
						t
						L f t ECL
T		18,221,975.88	12,514,142.66			/

D () : N III. (X)

P :

Item	B		P	P	f
	A	t			
On	t		t		
T	t		t		
On	384,617,398.37	7,488,540.70			1.95
T	384,617,398.37	7,488,540.70			

C () : N III. (X)

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Notes to the Financial Statements (Continued)

(III) Assets and Liabilities

3. Prepaid expenses	Balance at the beginning of the year	Cash and cash equivalents	Receivables	Other receivables	Due to related parties
Prepaid expenses	4,590,286.39	8,289,230.88		365,374.61	12,514,142.66
Prepaid expenses	4,775,548.84	3,379,914.39		666,922.53	7,488,540.70
Total	9,365,835.23	11,669,145.27		1,032,297.14	20,002,683.36
4. Assets					
Intangible assets					Assets held for sale
Assets held for sale					365,374.61

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(I) A

1. A

A	B		B	
	A	P	A	P
	(%)		(%)	
W 1	29,973,748.69	93.08	11,751,451.87	99.11
1-2	2,127,484.58	6.61	58,511.20	0.49
2-3	56,690.70	0.18	24,163.99	0.20
Q 3	43,300.00	0.13	24,300.00	0.20
T	32,201,223.97	100.00	11,858,427.06	100.00

附注五、非经常性损益明细表
 F
 (A 2022 RMB Y)

V. N
 () Ob

Item	B	B
I		
D		
O	37,195,219.68	29,925,487.99
T	37,195,219.68	29,925,487.99

(1) O

A	B	B
W 1	31,752,956.09	20,470,501.76
1 - 2	12,384,779.19	4,096,700.18
2 - 3	4,035,447.86	838,693.49
3 - 4	1,755,508.40	2,814,221.11
4 - 5	101,363.87	1,452,266.68
O 5	3,877,306.68	2,930,000.00
S	53,907,362.09	32,602,383.22
L : P	16,712,142.41	2,676,895.23
T	37,195,219.68	29,925,487.99

Notes to the Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets (continued)

(1) Other non-current assets (continued)

(2) Other non-current assets (continued)

Category	Bought from the company		Bought from the company		Bought from the company	Bought from the company		Bought from the company		Bought from the company
	Amount	(%)	Amount	(%)		Amount	(%)	Amount	(%)	
Prepaid expenses	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29	1,435,560.00	4.40	1,435,560.00	100.00	
Intangible assets										
Housing										
Unamortized										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										
Housing										
Cost										
Accumulated depreciation										
Net book value										

Notes to Financial Statements
F 2022
(A RMB Y)

V. N ()

() Ob (t)

(2) O ()

P V :

N	B	t	f	f

H Y				
H C.,L.	25,337,819.20	15,852,030.91	62.56	h h t

T	25,337,819.20	15,852,030.91		
---	---------------	---------------	--	--

D P V : P N III. (X)

P V :

N	Ob	t	f	f

P	28,569,542.89	860,111.50	3.01	
---	---------------	------------	------	--

T	28,569,542.89	860,111.50		
---	---------------	------------	--	--

C P V : P
N III. (X)

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

() Ob (t r)

(3) D

P f t	12- h ECL	t 1	t 2 L f t ECL (t t-)	t 3 L f t ECL (t t-)	t
B 2		1,241,335.23		1,435,560.00	2,676,895.23
B 2					
2 /					
-T 2					
-T 3					
-R 2					
-R 1					
P		141,793.04		15,852,030.91	15,993,823.95
R		485,492.80		1,435,560.00	1,921,052.80
W		37,523.97			37,523.97
W					
O					
B 2		860,111.50		15,852,030.91	16,712,142.41

Notes to Financial Statements
F 2022
(A RMB Y)

V. N ()

() Ob (t r)

(3) D ()

C :

B	12- ECL	t 1 ECL	t 2 L ^f t ECL (t t- ())	t 3 L ^f t ECL (t t- ())	t
B		31,166,823.22		1,435,560.00	32,602,383.22
B					
-T	2				
-T	3				
-R	2				
-R	1				
A		2,428,909.82		25,337,819.20	27,766,729.02
D		4,306,570.80		1,435,560.00	5,742,130.80
O		-719,619.35			-719,619.35
B		28,569,542.89		25,337,819.20	53,907,362.09

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

() Ob (t r)

(4) P , ,

	B	C	R	W	B
C t y					
P	1,435,560.00	15,852,030.91	1,435,560.00		15,852,030.91
P	1,241,335.23	141,793.04	485,492.80	37,523.97	860,111.50
T	2,676,895.23	15,993,823.95	1,921,052.80	37,523.97	16,712,142.41

O , a a a a a :

D t b f
t t f
N f t b

H a U a C 1,435,560.00 F R a M a
C D
A T , P a C

T 1,435,560.00

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets

(1) Other non-current assets

(5) Other non-current assets

Item	Amount
Other non-current assets	37,523.97

(6) Other non-current assets

Item	Amount	Amount
Depreciation	20,677,631.31	23,577,997.61
Prepaid expenses	816,666.30	4,228,330.66

五、非经常性损益明细表
 附：非经常性损益明细表
 2022
 (A 人民币元)

V. Non-recurring损益 (人民币元)

(I) Items

Item	Balance at the beginning of the period	Change during the period	Balance at the end of the period	Balance at the end of the period
Other non-recurring损益	3,697,607.74	3,697,607.74	2,242,027.51	2,242,027.51
Other non-recurring损益	54,633,789.63	54,633,789.63	54,277,273.72	54,277,273.72
Other non-recurring损益	58,331,397.37	58,331,397.37	56,519,301.23	56,519,301.23

(II) Other non-recurring损益

Item	Balance at the beginning of the period	Balance at the end of the period
Other non-recurring损益	196,008.48	137,228.50
Other non-recurring损益	269,072.88	321,191.35
Other non-recurring损益	287,243.41	348,266.00
Other non-recurring损益	752,324.77	806,685.85

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) L

Item	Balance at the beginning of the year		Changes during the year		Balance at the end of the year	
	Original balance	Adjusted balance	Original balance	Adjusted balance	Original balance	Adjusted balance
E	14,000,000.00				14,000,000.00	
T	14,000,000.00				14,000,000.00	

(I) L -t , ty t t

	Balance at the beginning of the year		Changes during the year		Balance at the end of the year			
Item	Original balance	Adjusted balance	Original balance	Adjusted balance	Original balance	Adjusted balance		
A								
H A								
M T C.,L.	13,156,356.09		-4,287,437.64		5,310,451.69	14,179,350.14		
W L								
Y H C.,L.	58,100,000.00	500,000.00				57,600,000.00		
Z H								
H M C.,L.	22,193,790.14		-1,090,147.47			21,103,642.67		
S S H								
M C C.,L.	23,198,356.89		-1,102,416.10			22,095,940.79		
C H								
K H C.,L.	18,687,211.65		74,969.38		400,000.00	18,362,181.03		
C Y H C.,L.	11,514,784.92		-1,309,633.45			10,205,131.47		
J Y S H C.,L.	5,191,069.69					5,191,069.69		
H Y H C.,L.								
(N)								
T	129,847,779.24	22,193,790.14	500,000.00	-7,714,705.28	5,310,451.69	400,000.00	5,191,069.69	143,546,246.10

N : O 10 A 2022, Z K H M (G) C.,L. (Z K), C 28% H Y H C.,L. (H Y), , T W L L Y H M C.,L. (L L) RMB14,000,000.00, S A C J H G S I E I F P (L.P.), C J P II M H S I E I F P (L.P.), T W L L H M C.,L., L L , RMB13,922,929.38 , Z K , H Y 33% , H Y B , H Y C Y H Y

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets

(1) Other non-current assets

Item	Balance at the beginning of the year	Balance at the end of the year
Funds from the government	63,116,852.05	65,812,274.58
Intangible assets	63,116,852.05	65,812,274.58
Total	63,116,852.05	65,812,274.58

V. N		(I) F		()		B		M		E		F	
2. D		t		t		t		t		t		t	
It		t		t		t		t		t		t	
1. O		t		t		t		t		t		t	
(1) B		745,833,959.90		142,218,120.78		6,548,724.87		68,038,620.62		962,639,426.17			
(2) I		811,977.80		25,247,491.51		6,016,909.41		9,508,145.59		181,611,758.16			
-P		811,977.80		14,854,645.52		2,906,555.91		5,748,234.46		24,321,413.69			
-T													
-I				10,392,845.99		3,110,353.50		3,759,911.13		17,263,110.62			
-O										140,027,233.85			
(3) D		70,270,990.67		65,654,865.68		3,162,440.49		25,386,159.55		164,474,456.39			
-D				12,438,192.49		658,984.47		3,310,725.18		16,407,902.14			
-D				5,259,711.00		565,764.12		2,213,845.28					
-O		70,270,990.67		47,956,962.19		1,937,691.90		19,861,589.09		140,027,233.85			
(4) B		676,374,947.03		101,810,746.61		9,403,193.79		52,160,606.66		979,776,727.94			

[illegible]

Net Profit _____ **ttt** _____ **ttt** _____
 F  2022
 (A  RMB Y )

V. N. ()

(II) C t , t

1. C

	B	152,497,399.68	43,795,718.15
It			
C		152,497,399.68	43,795,718.15
C			
T		152,497,399.68	43,795,718.15

2. $D \nsubseteq$

				B	I	B	B	I	B
It				B		B	B	I	B
W	K	T	C						
				311,600.00		311,600.00	782,356.00		782,356.00
T	N	Y	H				1,027,373.54		1,027,373.54
T									
L	Y	H		72,377,326.40		72,377,326.40	6,213,670.10		6,213,670.10
T									
P	C		H				7,504,860.00		7,504,860.00
T									
O	Y	H					27,288,058.64		27,288,058.64
T									
L	C	H		27,536,449.81		27,536,449.81	150,609.00		150,609.00
T									
Q	Y	H		16,073,697.42		16,073,697.42			
T									
J	S	H		35,508,167.99		35,508,167.99			
O				690,158.06		690,158.06	828,790.87		828,790.87
T				152,497,399.68		152,497,399.68	43,795,718.15		43,795,718.15

V. N
(III)C
3. M

Particulars (Rs. in Lakhs)									
Particulars	MB'0,000	B t	B t	I t	D t	B t	P t	A t	I t : C t
T									
L Y H	18,003.00	6,213,670.10	66,247,515.67			72,461,185.77	40.25	40.00	1,883,479.17 1,608,608.70 4.90 B
T									
P C H	1,897.75	7,504,860.00	17,107,073.00		24,611,933.00		100.00	100.00	O
T									
O Y H	4,047.80	27,288,038.64	11,021,933.76		38,310,012.40		100.00	100.00	O
T									
L C									
H	16,020.00	150,609.00	27,385,840.81			27,536,449.81	17.19	20.00	O
T									
Q Y									
H	9,848.00		16,073,697.42			16,073,697.42	16.32	15.00	O
T									
J									
H	6,666.00		35,508,167.99			35,508,167.99	54.15	55.00	O
T									
		41,157,197.74	173,344,248.65		62,921,945.40	151,579,500.99		1,883,479.17	1,608,608.70

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) h t- f- t

It	B	
	t t	t
1.O		
(1)B	363,270,419.51	363,270,419.51
(2)I	37,254,480.17	37,254,480.17
- N	21,847,297.56	21,847,297.56
- I	15,407,182.61	15,407,182.61
(3)D	81,876,743.78	81,876,743.78
- D	16,772,968.78	16,772,968.78
- D	65,103,775.00	65,103,775.00
(4)B	318,648,155.90	318,648,155.90
2.A		
(1)B	105,858,149.38	105,858,149.38
(2)I	38,189,335.84	38,189,335.84
- P	38,189,335.84	38,189,335.84
(3)D	15,803,080.90	15,803,080.90
- D	4,949,246.94	4,949,246.94
- D	10,853,833.96	10,853,833.96
(4)B	128,244,404.32	128,244,404.32
3.I		
(1)B		
(2)I		
(3)D		
(4)B		
4.C		
(1)C	190,403,751.58	190,403,751.58
(2)C	257,412,270.13	257,412,270.13

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(I) I t

It	L		M		C	
	h	h	f	f	t	t
1.O						
(1)B	102,977,820.17	3,061,637.13	14,252,889.08	129,837,000.00	32,400,000.00	282,529,346.38
(2)I	25,616,355.88		-3,433,306.28	29,000,000.00		51,183,049.60
-P	19,841,690.88		-4,460,006.28			15,381,684.60
-I	5,774,665.00		1,026,700.00	29,000,000.00		35,801,365.00
(3)D			1,141,970.00			1,141,970.00
-D			508,000.00			508,000.00
-D			633,970.00			633,970.00
(4)B	128,594,176.05	3,061,637.13	9,677,612.80	158,837,000.00	32,400,000.00	332,570,425.98
2.A						
(1)B	9,610,253.66	360,120.18	9,441,245.79	27,772,369.86	7,353,571.43	54,537,560.92
(2)I	2,889,207.41	330,465.48	1,799,113.48	17,315,075.42	1,500,000.00	23,833,861.79
-P	2,889,207.41	330,465.48	1,072,248.57	17,315,075.42	1,500,000.00	23,106,996.88
-I			726,864.91			726,864.91
(3)D			485,345.23			485,345.23
-D			39,066.67			39,066.67
-D			446,278.56			446,278.56
(4)B	12,499,461.07	690,585.66	10,755,014.04	45,087,445.28	8,853,571.43	77,886,077.48
3.I						
(1)B						
(2)I						
(3)D						
(4)B						
4.C						
(1)C	116,094,714.98	2,371,051.47	-1,077,401.24	113,749,554.72	23,546,428.57	254,684,348.50
(2)C	93,367,566.51	2,701,516.95	4,811,643.29	102,064,630.14	25,046,428.57	227,991,785.46

Net Profit attributable to the Company
F
(A) 2022 RMB Y ()

Basic
EPS

D

()

()

I

Basic
EPS

Net Profit attributable to the Company
F
(A) 2022 RMB Y ()

V. N
() G
1. C

WenZhou KangNing Hospital Co., Ltd.

F 2022
(A RMB Y)

V. N ()

() G ()

2. I

A C ;

U : RMB'0,000

A 31 D 2022

N Y H C.,L .	927.18
H Y P H C.,L .	69.03
G Y H C.,L .	154.90
W N P S H C.,L .	778.49
B Y H C.,L .	2,298.73
W Y H T C.,L .	15.11
H K H C.,L .	506.9
C K P H C.,L .	684.33
W C H C.,L .	1,941.63
P C Y H C.,L .	5,177.02
H Y N S C.,L .	127.26
Z F N T C.,L .	32.60
J S H C.,L .	506.03

T 13,219.21

I , C . I

North F
F 2022
(A RMB Y)

V. N ()

() G (t)

3. P ,

y t f t t					
A					
A t t					
f y P t y N t f t P t					
A t f t t (/ y/y) b t t t					
N Y H C.,L .	219	337	2.50%	21.33%	14.00%
H Y P Y H C.,L .	267	289	2.50%	20.60%	14.00%
G Y H C.,L .					
W N P Y S Y H C.,L .	323	291	2.50%	22.06%	14.00%
B Y H C.,L .	32	1,810	2.50%	-2.40%	14.00%
W Y H T Y C.,L .					
H K H C.,L .	211	196	2.50%	16.94%	14.00%
C K P Y H C.,L .	315	205	2.50%	17.48%	14.00%
W C H C.,L .	325	546	2.50%	9.59%	14.00%
C K H H C.,L .	213	400	2.50%	19.01%	14.00%
P Y C Y H C.,L .	425	594	2.50%	6.71%	14.00%
P Y H H C.,L .	270	273	2.50%	15.82%	14.00%
H Y N S C.,L .	72	117	2.50%	21.92%	14.00%
J Y S H C.,L .	382	284	2.50%	22.65%	14.00%

O :

A ; -

五、非经常性损益明细表
 附：非经常性损益明细表
 2022
 (A 人民币元)

V. Non-recurring gains and losses ()

() Gain ()

4. Investment income

I 2022, COVID-19, B Y H C., L. D. C. RMB10,345,460.56.

(I) Loss -

Item	Balance at the beginning of the year	Balance at the end of the year	Balance at the end of the year	Balance at the end of the year	Balance at the end of the year
R	150,328,412.40	100,049,601.67	46,186,845.31	14,777,100.83	189,414,067.93
L	172,625.00	94,613.90	94,967.96		172,270.94
T	150,501,037.40	100,144,215.57	46,281,813.27	14,777,100.83	189,586,338.87

(II) Deferred income tax assets and liabilities

1. Deferred income tax assets

Item	Balance at the beginning of the year	Balance at the end of the year	Balance at the end of the year	Balance at the end of the year	Balance at the end of the year
P	16,979,155.87	3,164,380.59	8,026,079.93		1,687,621.09
U					
D	50,169,236.15	8,217,114.53	18,012,806.84		4,503,201.71
D	4,390,510.38	1,097,627.60	4,653,187.96		1,163,296.99
S	54,688,502.33	8,203,275.35	46,552,302.33		6,982,845.35
T	126,227,404.73	20,682,398.07	77,244,377.06		14,336,965.14

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(II) D f t f t (t)

2. D

It	B t h f h	B a a	T a	D f t D
A	148,564,631.76	37,141,157.94	144,340,394.12	36,085,098.53
C	13,116,852.07	1,967,527.81	15,812,274.60	2,371,841.19
O -	6,620,111.12	1,439,193.06	6,958,909.45	1,418,850.23
T	168,301,594.95	40,547,878.81	167,111,578.17	39,875,789.95

(III) Ob - t t

I	B t h f h	B a a	P f C y	P	G y
P	6,936,000.00	6,936,000.00	6,936,000.00		6,936,000.00
P	6,605,047.21	6,605,047.21	130,386.60		130,386.60
T			14,000,000.00		14,000,000.00
T	13,541,047.21	13,541,047.21	21,066,386.60		21,066,386.60

(I) h t-t

It	B t h f	B a a
S	195,000,000.00	200,000,000.00
G	8,000,000.00	54,050,000.00
T	203,000,000.00	254,050,000.00

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(1) Intangible Assets

Item	Balance at the beginning of the year	Increases	Decreases	Balance at the end of the year
Patent rights		13,922,929.38		13,922,929.38
Total		13,922,929.38		13,922,929.38

(2) Long-term Equity Investments

Item	Balance at the beginning of the year	Increases	Decreases	Balance at the end of the year
Long-term equity investments		997,944.00		997,944.00
Total		997,944.00		997,944.00

(3) Available-for-Sale Financial Assets

There are no available-for-sale financial assets at the end of the reporting period.

Item	Balance at the beginning of the year	Increases	Decreases	Balance at the end of the year
Warrant		84,193,738.77		84,193,738.77
1-2 years		1,161,389.02		1,161,389.02
2-3 years		71,968.47		71,968.47
Over 3 years		345,965.27		345,965.27
Total		84,193,738.77		84,193,738.77

附注五、非经常性损益明细表
 F 2022
 (A RMB Y)

V. N ()

(III) A

Item	B	B
	h f	h f
A	29,436,207.46	16,275,602.70
R	458,629.04	
T	29,894,836.50	16,275,602.70

(I) C t t t

Item	B	B
	h f	h f
A		3,240.59
T		3,240.59

() E y f t y

1. L y y

Item	B	I	D	B
	h f	h f	h f	h f
S	57,969,287.42	498,871,976.49	488,702,553.33	68,138,710.58
P	2,518,896.85	30,311,176.43	30,410,434.15	2,419,639.13
T	60,488,184.27	529,183,152.92	519,112,987.48	70,558,349.71

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

() E f t y (t ,)

2. L -

Item	Balance at the beginning of the year	Increase	Decrease	Balance at the end of the year
(1) Wages, salaries, bonuses, etc.	56,230,979.61	447,906,594.96	437,976,426.00	66,161,148.57
(2) Social security	87,835.30	10,184,665.65	9,965,118.81	307,382.14
(3) Short-term employee benefits	1,334,394.89	19,527,025.66	19,397,236.12	1,464,184.43
I : Medical insurance	1,290,685.28	18,813,797.48	18,678,735.17	1,425,747.59
Welfare fund	38,841.61	641,567.33	643,107.24	37,301.70
Maternity insurance	4,868.00	55,652.85	60,096.21	424.64
Other		16,008.00	15,297.50	710.50
(4) Housing fund				

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(I) P

Item	Balance at the beginning of the year	Balance at the end of the year
VAT	2,399,813.52	2,194,179.27
E	26,859,279.46	22,060,348.34
I	1,260,918.02	1,102,372.67
C	163,205.29	39,305.94
P	2,292,516.47	4,544,055.56
E	116,587.33	28,135.83
L	387,329.69	250,083.20
S	25,663.04	16,848.52
E	1,696.00	

Notes to the Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets

(II) Other non-current assets (continued)

2. Development costs

Item	Balance at the beginning of the year	Balance at the end of the year
Original value		
Development costs	735,000.00	86,550.00
Total	735,000.00	86,550.00

3. Other intangible assets

Item	Balance at the beginning of the year	Balance at the end of the year
Patent rights	25,932,146.03	8,703,936.40
Patent rights	7,000,000.00	15,000,000.00
Workforce	3,682,272.62	7,166,038.37
Domain names	1,900,552.80	1,094,722.20
Copyrights	17,695,375.57	7,496,808.30
Patent rights	4,374,261.21	4,312,000.00
Assets	3,673,024.53	6,981,466.40
Other	6,624,054.06	4,025,654.97
Total	70,881,686.82	54,780,626.64

Notes to the Financial Statements
F 2022
(A RMB Y)

V. Non-current Assets ()

(III) Non-current Assets

Item	Balance at the end of the year	Balance at the beginning of the year
Long-term equity investments	22,470,000.00	18,200,000.00
Long-term receivables	99,580,000.00	
Long-term prepaid expenses	25,548,324.39	30,040,752.22
Total	147,598,324.39	48,240,752.22

(I) Long-term equity investments

Item	Balance at the end of the year	Balance at the beginning of the year

五、非经常性损益明细表
 附注 2022
 (A 人民币元)

V. N ()

(I) L -t y

It	B t f	B a a
L -	42,404,938.54	
S		
T	42,404,938.54	

O : -

It	B t f	B a a
A	141,984,938.54	
I : U	9,382,772.07	
L : L -	99,580,000.00	
T	42,404,938.54	

(II) D f

It	B a a	I a	D a	B t f	R a
G	9,341,683.00		303,792.00	9,037,891.00	

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(I) Intangible Assets

On December 31, 2022, the Company has the following intangible assets:

(1) For the year ended December 31, 2022, the Company has the following intangible assets:

(2) In 2022, the Company's intangible assets with a carrying amount of RMB4,698,718.86 were fully impaired due to the significant decline in their market value. The impairment loss was recognized in the profit and loss account.

(II) Other Non-current Assets

Item	Balance at the beginning of the year	Balance at the end of the year	Decrease	Balance at the end of the year
Share-based payment	38,399,577.13	38,399,577.13		38,399,577.13
Total	38,399,577.13	38,399,577.13		38,399,577.13

On December 31, 2022:

The share-based payment is related to the Company's share incentive plan. The plan was approved by the shareholders' meeting on December 31, 2021. The plan is to grant restricted shares to the Company's employees. The restricted shares are subject to a lock-up period of 10% of the total shares outstanding. The restricted shares are granted at a price of RMB50.00 per share. The restricted shares are granted to the employees on December 31, 2021. The restricted shares are subject to a lock-up period of 10% of the total shares outstanding. The restricted shares are granted to the employees on December 31, 2021. The restricted shares are subject to a lock-up period of 10% of the total shares outstanding.

North E
F 2022
(A RMB Y)

Wen Zhou Kang Ning Hospital Co., Ltd.
F 2022
(A RMB Y)

V. N ()

(III)

1. A

Item	A	C	A	C
Ma	1,366,816,938.51	1,040,114,649.97	1,202,774,377.74	897,111,635.75
O	118,086,103.74	91,857,292.80	94,655,992.09	71,320,820.01
T	1,484,903,042.25	1,131,971,942.77	1,297,430,369.83	968,432,455.76

B :

Item	A	A
R	1,366,816,938.51	1,202,774,377.74
I : P	305,118,303.27	267,588,282.25
T	1,061,698,635.24	935,186,095.49
R	118,086,103.74	94,655,992.09
I : W	85,464,736.39	51,613,429.22
M	3,000,000.00	2,970,297.00
R	8,067,969.32	7,515,329.40
R		16,043,547.63
O	21,553,398.03	16,513,388.84
T	1,484,903,042.25	1,297,430,369.83

2. D

T ,

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Notes to the Financial Statements (Continued)

(III) Significant accounting policies

It

As of the end of the reporting period, the Company has no significant accounting policies that have changed compared with the previous period.

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(L)G

Item	Amount	Amount
E	106,839,736.87	92,095,322.35
C	22,821,067.41	11,791,502.03
D	12,364,390.29	10,327,372.91
R	7,928,268.21	7,688,976.40
A	7,169,511.48	7,803,052.34
A	6,366,300.00	1,222,900.00
O	5,452,608.66	5,171,123.31
A	5,226,706.30	3,986,627.45
E	4,539,506.45	2,946,383.00
E	4,412,652.14	8,414,462.03
T	4,358,637.42	2,835,174.29
P	2,798,524.34	3,204,882.36
H	2,653,266.15	4,644,062.36
C	2,527,587.52	3,580,020.08
P	2,521,353.37	1,319,556.59
O	2,099,610.09	3,313,286.64
U	1,889,937.19	1,974,023.35
P		96,657.59
O	3,917,508.51	3,956,503.74
T	205,887,172.40	176,371,888.82

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(LI) h t

Item	Amount	Amount
E	29,575,455.47	24,627,424.22
O	1,164,368.95	1,346,035.33
D	550,065.23	594,882.24
P	400,114.92	311,882.70
A	76,467.92	
T	68,877.00	134,907.60
C	58,690.00	
T	30,200.00	
T	19,682.96	76,999.34
U	11,090.48	
C	3,000.00	
O	1,069,974.86	870,041.96
T	33,027,987.79	27,962,173.39

(LII) F

Item	Amount	Amount
I	45,149,998.30	36,267,756.91
I : I	11,935,506.62	14,290,203.16
L : I	2,761,765.05	1,691,366.88
F	-78,462.87	38,704.15
F	1,999,946.76	3,043,331.77
T	44,309,717.14	37,658,425.95

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(III) Other Non-current Assets

Item	Amount at the end of the year	Amount at the beginning of the year
Goodwill	14,602,195.91	13,486,446.80
Available-for-sale financial assets	37,171.75	
Long-term equity investments	162,213.15	133,188.26
Other	106,130.00	
Total	14,907,710.81	13,619,635.06

Goodwill

Item	Amount at the end of the year	Amount at the beginning of the year	Change
Intangible assets	859,807.09	1,231,900.37	Decrease
Software	3,408,933.78	3,325,154.99	Increase
Software	1,018,900.00	2,270,000.00	Decrease
Other intangible assets			
Software	973,813.11	244,079.31	Increase
Intangible assets			
Software	638,519.98		Increase
Software	600,000.00	50,000.00	Increase
Software	600,000.00		Increase
Software	440,197.00	814,795.52	Decrease
Software	311,520.00	744,608.99	Decrease
Software	303,792.00	303,792.00	Decrease
Software	300,000.00		Increase
Software	284,000.00	284,000.00	Decrease
Software	249,000.00		Increase
Software			
Software	238,400.00		Increase

2022 年度 财务报表附注 (A 股上市)

2022 年度
 RMB Y

V. N

(LIII) Ob

GV

Item	Amount	Amount	Amount
COVID-19			
H C P	197,750.00		I -
H C C	174,653.70		I -
U S B B H R	138,796.96		I -
O S	120,835.00		I -
S	117,625.00		I -
W - D H			
S C	64,000.00		I -
H B Y D ,H	63,971.59		I -
I			
D R B P	55,332.00	50,000.00	I -
S I P	50,000.00		I -
S	90,000.00	168,696.99	I -
S D P ' H	40,000.00	40,000.00	I -
T M F S A T			
	38,201.19		I -
E	36,218.55		I -
T 2022			
E I B Y C	22,045.69		I -
S F B N M B P A	20,000.00		I -
T - P B			
W E E B	20,000.00		I -
T -			
H C L D	20,000.00		I -
T - C B			
W E E B	20,000.00		I -

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(III) Other Non-current Assets

Other Non-current Assets (in RMB Yuan)

Item	Amount at the end of the year	Amount at the beginning of the year	Change
Receivables from related parties			
D.C. P.V.	17,000.00		I -
Share of profit or loss of equity investees			
E.C. J.D.	13,610.61		I -
Long-term receivables			
R.I. P.	12,000.00		I -
Long-term equity investments			
Y.C. H.B.'S. P. H.S. F.	10,200.00	13,500.00	I -
Long-term prepayments			
T.	7,000.00		I -
Long-term prepayments			
T. F.	6,700.00		I -
Long-term prepayments			
S. W. H. P. F. M. C.	4,433.33		I -
Long-term prepayments			
P. C. H.B.'S. F.	3,000.00	1,904,299.94	I -
Long-term prepayments			
L. C. C. D. C. P. F. M.	3,000.00		I -
Long-term prepayments			
S.			
Long-term prepayments			
W. H. P. F. M. C. 'H.			
Long-term prepayments			
P. F. S.	1,833.33		I -
Long-term prepayments			
Y. D. P. D. 'F. R.			
Long-term prepayments			
C. R. , D. B.	1,600.00		I -
Long-term prepayments			
E. A. S.	1,500.00	74,237.34	I -
Long-term prepayments			
M. S.	1,380.00		I -
Long-term prepayments			
P. H. S. F. L. D. H. C.	1,000.00		I -
Long-term prepayments			
P. C. P. F. E. M. -C.			
Long-term prepayments			
T. HIV, S. H. B.	476.00		I -
Long-term prepayments			
P. C. P. F. F. P. B. D.			
Long-term prepayments			
P.	450.00		I -
Long-term prepayments			
O. D. M. S. A. 'S.			
Long-term prepayments			
M. A. D. R.	360.00		I -

North E
F 2022
(A RMB Y)

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(I) Goodwill

Item	Amount at the end of the period	Amount at the beginning of the period
Initial recognition		
From business combination	-2,054,396.53	8,407,356.31
From other sources		
From business combination	-13,922,929.38	
From other sources		1,010,034.42
Total	-15,977,325.91	9,417,390.73

(II) Intangible Assets

Item	Amount at the end of the period	Amount at the beginning of the period
Initial recognition		
From business combination	11,260,563.08	3,005,695.74
From other sources	13,930,978.11	-865,499.29
Total	25,191,541.19	2,140,196.45

(III) Assets Held for Sale

Item	Amount at the end of the period	Amount at the beginning of the period
Initial recognition		
From business combination	10,345,460.56	6,179,290.37
Total	10,345,460.56	6,179,290.37

五、非经常性损益对公司净利润的影响

2022年度非经常性损益对公司净利润的影响

(单位:人民币元)

五、非经常性损益对公司净利润的影响

(单位:人民币元)

A

-

Item	Amount	Amount	Amount
Government grants	406,184.95	-101,512.90	406,184.95
Other non-recurring gains	406,184.95	-101,512.90	406,184.95
Other non-recurring gains		22,109.35	
Total	406,184.95	-79,403.55	406,184.95

(单位:人民币元)

A

-

Item	Amount	Amount	Amount
Government grants	12,737.42	154,603.42	12,737.42
Other non-recurring gains	12,737.42	154,603.42	12,737.42
Disposal of non-current assets	7,435,774.26	9,470,530.18	7,435,774.26
Government grants	55,075.00	265,600.00	55,075.00
Government grants	60.10		60.10
Provision of non-current assets	35,711.51		35,711.51
Disposal of non-current assets		1,800,000.00	
Government grants	12,000.00		12,000.00
Government grants	15,000.00		15,000.00
Other non-recurring gains	987,619.57	145,198.20	987,619.57
Total	8,553,977.86	11,835,931.80	8,553,977.86

Notes to the Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets

(II) Intangible assets

Goodwill

Item	Amount at the beginning of the year	Amount added during the year	Amount reduced during the year
Subsidiary goodwill			
Wenzhou Kangning Hospital Co., Ltd.		100,000.00	
Wenzhou Kangning Hospital Co., Ltd.			
Wenzhou Kangning Hospital Co., Ltd.		150,000.00	
Wenzhou Kangning Hospital Co., Ltd.	5,000.00		
Wenzhou Kangning Hospital Co., Ltd.			
Wenzhou Kangning Hospital Co., Ltd.	75.00		
Wenzhou Kangning Hospital Co., Ltd.	5,000.00		
Wenzhou Kangning Hospital Co., Ltd.	40,000.00		
Wenzhou Kangning Hospital Co., Ltd.	5,000.00		
Wenzhou Kangning Hospital Co., Ltd.		15,600.00	
Total	55,075.00	265,600.00	

(L) Intangible assets

A

Item	Amount at the beginning of the year	Amount added during the year	Amount reduced during the year
Land use rights	1,587,610.46	165,976.73	1,587,610.46
Patent rights	1,587,610.46	165,976.73	1,587,610.46
Copyrights	3,927,631.03	3,333,396.94	3,927,631.03
Software	521,375.57		521,375.57
Other intangible assets	99,809.90		99,809.90
Patent rights	267,628.43		267,628.43
Land use rights	1,754,450.54	3,398,511.21	1,754,450.54
Other	1,182,532.80	1,738,698.54	1,182,532.80
Total	9,341,038.73	8,636,583.42	9,341,038.73

N t t h F		t t t	
F	2022		
(A	RMB Y	)	
V. N		(	)
(LI) I	t		
1. T			
		A , t f h	A
It		t	
C		40,192,565.61	26,919,820.08
D		-13,618,853.12	

V. N. ()

1. B_{max} $\rightarrow$ B_{min}

It is not clear whether the β values are the same for all the α values. A

Category	Value	Value
C	-24,220,782.31	44,035,995.21
W	74,600,300.00	72,140,300.00
B	-0.32	0.61
I	-0.32	0.61

2. D

[illegible]

C							-24,220,782.31	44,035,995.21
W								
D							74,600,300.00	74,600,300.00
I	:	D					-0.32	0.59
	D						-0.32	0.59

Ninth Edition

F 2022
(A RMB Y)

V. N. ()

(LIII) , t y f t t h t t t f y t

T
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 84

| It | A | A |
|----|------------------|------------------|
| E | 538,910,495.15 | 435,967,572.12 |
| P | 417,971,255.04 | 353,105,992.03 |
| C | | 15,204,373.00 |
| D | 53,029,785.07 | 45,173,131.23 |
| D | 38,189,335.84 | 45,435,380.70 |
| A | 22,991,163.56 | 15,010,629.62 |
| A | 46,397,646.59 | 38,371,918.45 |
| H | 17,904,619.09 | 15,472,884.97 |
| C | 66,553,544.09 | 57,050,465.71 |
| U | 29,928,936.30 | 24,096,157.46 |
| O | 23,086,080.63 | 21,047,712.17 |
| T | 27,657,239.14 | 25,603,836.37 |
| C | 28,302,685.02 | 13,820,361.56 |
| A | 6,366,300.00 | 1,222,900.00 |
| P | 3,526,992.98 | 2,990,339.08 |
| T | 5,332,487.78 | 4,416,545.06 |
| O | 8,492,200.89 | 9,312,807.52 |
| S | 12,214,418.85 | 15,932,752.35 |
| O | 39,035,944.67 | 43,866,151.22 |
| T | 1,385,891,130.69 | 1,183,101,910.62 |

Notes to the Financial Statements
 F 2022
 (A RMB Y)

V. N ()

(LI) It

1. G

| It | A | A |
|-----|----------------|---------------|
| R | 40,253,328.59 | 45,945,728.57 |
| G | 14,633,117.41 | 13,579,087.19 |
| L | 8,067,969.32 | 7,012,773.24 |
| D | 10,116,855.54 | 12,851,693.57 |
| I | 12,751,158.99 | 14,960,534.77 |
| N - | 1,035,391.18 | 1,870,927.58 |
| R | 14,000,000.00 | |
| T | 100,857,821.03 | 96,220,744.92 |

2. G

| It | A | A |
|-----|----------------|---------------|
| I - | 30,632,892.49 | 23,313,110.97 |
| C | 82,155,141.49 | 54,235,967.08 |
| D | 6,608,712.31 | 6,714,560.33 |
| N - | 2,927,440.32 | 4,469,403.02 |
| F | 1,082,364.51 | 1,442,594.04 |
| R | 12,498,972.00 | |
| T | 135,905,523.12 | 90,175,635.44 |

3. G

| It | B | B |
|----|--------------|---|
| N | 8,770,704.43 | |
| T | 8,770,704.43 | |

Notes to the Financial Statements
 For the Year Ended December 31, 2022
 (All amounts in RMB Yuan, unless otherwise specified)

V. Notes to the Financial Statements (Continued)

(LI) It is the liability of the company (including the liability of the company)

4. The company's liability is as follows:

| Item | Amount at the end of the year | Amount at the beginning of the year |
|----------------------|-------------------------------|-------------------------------------|
| Guaranteed liability | 150,684,059.10 | |
| Guaranteed liability | 736,190.90 | |
| Total | 151,420,250.00 | |

5. The company's liability is as follows:

| Item | Amount at the end of the year | Amount at the beginning of the year |
|----------------------|-------------------------------|-------------------------------------|
| Guaranteed liability | 8,096,992.56 | |
| Guaranteed liability | 43,524,302.81 | 44,807,765.61 |
| Fund | 4,500,000.00 | 750,000.00 |
| Guaranteed liability | - | 15,118,800.00 |
| Total | 56,121,295.37 | 60,676,565.61 |

2022 年 12 月 31 日止

人民币元

净资产

(L)

1. S

| | 人民币元 | 人民币元 |
|-------|-----------------|----------------|
| 1. R | | |
| N | -10,968,838.36 | 40,860,230.05 |
| A : C | 25,191,541.19 | 2,140,196.45 |
| P | 10,345,460.56 | 6,179,290.37 |
| D | 53,029,785.07 | 48,274,868.81 |
| C | | |
| D | 38,189,335.84 | 41,779,572.06 |
| A | 22,991,163.56 | 14,530,192.10 |
| A | 46,397,646.59 | 38,836,785.71 |
| L | | |
| | -406,184.95 | 79,403.55 |
| L | 1,574,873.04 | 11,373.31 |
| L | 15,977,325.91 | -9,417,390.73 |
| F | 45,071,535.43 | 36,306,461.06 |
| I | -2,850,458.27 | -6,937,845.27 |
| D | -6,345,432.93 | 27,745,384.58 |
| I | 672,088.86 | 14,843,351.28 |
| D | -1,812,096.14 | -19,010,829.84 |
| D | -137,055,559.27 | -37,743,452.80 |
| I | 127,218,378.32 | -4,581,092.21 |
| O | | |
| N | 227,220,564.45 | 193,896,498.48 |
| 2. S | | |
| C | | |
| C | | |
| F | | |
| 3. N | | |
| G | 258,595,990.97 | 188,734,845.77 |
| L : G | 188,734,845.77 | 200,092,665.42 |
| A : G | | |
| L : G | | |
| N | 69,861,145.20 | -11,357,819.65 |

五、合并现金流量表

单位：人民币元
2022年度

五、合并现金流量表

(单位：人民币元)

2. 经营活动产生的现金流量

人民币元

| | |
|-----------------|---------------|
| 经营活动产生的现金流量 | |
| 销售商品、提供劳务收到的现金 | 54,309,855.16 |
| 收到的税费返还 | |
| 收到其他与经营活动有关的现金 | 21,684,900.00 |
| 经营活动现金流入小计 | 32,624,955.16 |
| 购买商品、接受劳务支付的现金 | 624,153.88 |
| 支付给职工以及为职工支付的现金 | 624,153.88 |
| 支付的各项税费 | |
| 支付其他与经营活动有关的现金 | |
| 经营活动现金流出小计 | 53,685,701.28 |

3. 投资活动产生的现金流量

人民币元

| | | |
|---------------------------|----------------|----------------|
| 投资活动产生的现金流量 | | |
| 收回投资收到的现金 | 258,595,990.97 | 188,734,845.77 |
| 取得投资收益收到的现金 | 454,907.26 | 971,773.72 |
| 处置固定资产、无形资产和其他长期资产收回的现金净额 | | |
| 处置子公司及其他营业单位收到的现金净额 | 257,534,338.59 | 187,484,938.31 |
| 收到其他与投资活动有关的现金 | 606,745.12 | 278,133.74 |
| 投资活动现金流入小计 | | |
| 购建固定资产、无形资产和其他长期资产支付的现金 | | |
| 投资支付的现金 | | |
| 取得子公司及其他营业单位支付的现金净额 | | |
| 支付其他与投资活动有关的现金 | | |
| 投资活动现金流出小计 | | |
| 投资活动产生的现金流量净额 | | |
| 筹资活动产生的现金流量 | | |
| 吸收投资收到的现金 | | |
| 发行债券收到的现金 | | |
| 收到其他与筹资活动有关的现金 | | |
| 筹资活动现金流入小计 | | |
| 偿还债务支付的现金 | | |
| 分配股利、利润或偿付利息支付的现金 | | |
| 支付其他与筹资活动有关的现金 | | |
| 筹资活动现金流出小计 | | |
| 筹资活动产生的现金流量净额 | | |
| 现金及现金等价物净增加额 | | |
| 期初现金及现金等价物余额 | | |
| 期末现金及现金等价物余额 | | |

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(L I) A h t t h t-f

C y t

| It | f h | R |
|----|----------------|---|
| M | 498,972.00 | B |
| | 12,000,000.00 | P |
| F | 35,612,151.67 | C |
| | 73,406,248.95 | S |
| I | 6,107,838.02 | C |
| T | 133,942,408.61 | |

(L II) G t t

P N V (XLIII) N V (XLIX)

VI. C

(I) B t t t

1. B

f C t f P t f
t f t f t t
N f t t t t (%)

Notes to the Financial Statements

F 2022
(A RMB Y)

VI. C ()

(I) B t t t (t)

2. C

Y Y J S Z F

Notes to the Financial Statements
F 2022
(A RMB Y)

VI. C ()

(I) B ()

2. C (C)

(2) I J 2022, Z K H M (G) C L ()
Z K), C C J Y
X , Z F N T C , L . ()
Z F), S ' A Z F
N T C , L , C C RMB3,000,000.00
RMB2,673,987.56 Z
F , RMB326,012.44.

3. I Y Y J S Z F

| | Y | Y | J | S | Z | F |
|-----|---------------|---------------|---------------|---------------|--------------|--------------|
| | Y | Y | J | S | Z | F |
| A : | 59,544,389.38 | 46,544,389.38 | 37,912,065.31 | 21,595,600.11 | 3,596,967.56 | 3,596,967.56 |
| G | | | 624,153.88 | 624,153.88 | 3,003,084.38 | 3,003,084.38 |
| R | 3,060,406.64 | 3,060,406.64 | 7,552,399.46 | 7,552,399.46 | | |
| I | | | 505,619.01 | 504,706.60 | 590,783.18 | 590,783.18 |
| O | | | 22,965.97 | 22,965.97 | | |
| F | 4,043,853.80 | 4,043,853.80 | 847,808.30 | 394,720.51 | 3,100.00 | 3,100.00 |
| C | | | 6,651,653.69 | 6,651,653.69 | | |
| I | 13,299,835.09 | 299,835.09 | 15,862,465.00 | | | |
| L - | 24,864,697.08 | 24,864,697.08 | | | | |
| O - | 14,275,596.77 | 14,275,596.77 | 5,845,000.00 | 5,845,000.00 | | |
| L : | 17,960,741.79 | 17,960,741.79 | 8,244,110.73 | 4,164,994.43 | 422,980.00 | 422,980.00 |
| B | | | | | | |
| P | 14,710,741.79 | 14,710,741.79 | 4,099,565.00 | 4,099,565.00 | 261,041.74 | 261,041.74 |
| E | | | 618,827.28 | 618,827.28 | 159,133.43 | 159,133.43 |
| T | | | -553,397.85 | -553,397.85 | 2,804.83 | 2,804.83 |
| D | 3,250,000.00 | 3,250,000.00 | 4,079,116.30 | | | |
| N | 41,583,647.59 | 28,583,647.59 | 29,667,954.58 | 17,430,605.68 | 3,173,987.56 | 3,173,987.56 |
| L : | | | 15,130,745.84 | 8,889,661.19 | 500,000.00 | 500,000.00 |
| N | 41,583,647.59 | 28,583,647.59 | 14,537,208.74 | 8,540,944.49 | 2,673,987.56 | 2,673,987.56 |

M : T C

Notes to the Financial Statements
F 2022
(A RMB Y)

VI. C ()

(III) 2022 12 31

T 2022 12 31 Z H H RMB7.23 . A
, C 47.48% Z H H

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

VII.1

(I) Investment in subsidiaries

1. Subsidiaries

| | | Percentage of ownership (%) | |
|-----------------|-----------------|-----------------------------|-------------------|
| Subsidiary Name | Business Nature | Percentage of ownership | Investment Amount |
| | | (0000'Yuan) | Investment Amount |

Notes to the Financial Statements
F 2022
(A RMB Y)

VII.I ()

(I) I t t (t)

1. S G ()

| N f, y | y f | P | P f | N b f | t | h h (%) | | |
|----------------|-----|---|-----|----------|--------|---------|-----|---------|
| | | | | | | D t | I t | M b f t |
| (0000') | | | | | | | | |
| Z Y H T LLC | H | H | T | 2,040.82 | 98.00 | I | | |
| C.,L. | | | | | | | | |
| W Y D C.,L. | W | W | D | 50 | 100.00 | I | | |
| Y M H E-H LLC | W | W | H | 500 | 100.00 | I | | |
| (W)C.,L. | | | | | | | | |
| Z D P LLC | W | W | P | 1,000 | 80.00 | I | | |
| C.,L. | | | | | | | | |
| C K P LLC | C | C | M | 2,700 | 64.55 | B | | |
| H C.,L. | | | | | | | | |
| C Q I K LLC | H | H | M | 1,000 | 100.00 | I | | |
| H C.,L. | | | | | | | | |
| H Y M E LLC | H | H | T | 500 | 100.00 | I | | |
| R&DC.,L. | | | | | | | | |
| H Y N S LLC | H | H | N | 100 | 100.00 | I | | |
| C.,L. | | | | | | | | |
| L C H C.,L. | T | T | M | 5,000 | 100.00 | I | | |
| S Y H LLC | S | S | M | 6,000 | 55.00 | I | | |
| P Y H H LLC | J | J | M | 1,660 | 100.00 | I | | |
| C.,L. | | | | | | | | |
| (浦江怡寧黃鋒醫院有限公司) | | | | | | | | |
| C K H LLC | H | H | M | 1,000 | 100.00 | I | | |
| H C.,L. | | | | | | | | |
| Q K H C.,L. | Q | Q | M | 5,000 | 100.00 | I | | |
| C.,L. | | | | | | | | |
| Q Y N C LLC | Q | Q | M | 1,000 | 100.00 | I | | |
| C.,L. | | | | | | | | |
| Y K H C.,L. | Y | Y | M | 100 | 100.00 | I | | |
| L K H C.,L. | T | T | M | 200 | 80.00 | I | | |
| O Y E H C.,L. | W | W | M | 1,000 | 100.00 | I | | |
| L. | | | | | | | | |
| Q K H C.,L. | L | L | M | 3,200 | 100.00 | I | | |
| S Y M I LLC | S | S | M | 1,000 | 100.00 | I | | |
| C.,L. | | | | | | | | |

Notes to Financial Statements
2022
(Amount in RMB Yuan)

| | | | | | Ownership (%) | | |
|---|-------------------|--------------------------|----------------------|-------------------|---------------|--------|-------------------------------------|
| Investor Name | Investment Amount | Proportion of Investment | Proportion of Shares | Investment Amount | (0000'Yuan) | Direct | Indirect |
| Wenzhou Kangning Hospital Co., Ltd. LLC | W | W | M | 2,585.98 | 100.00 | B | |
| | | | | | | | Wenzhou Kangning Hospital Co., Ltd. |

(

(

(

(

(

$$(II) \quad I = t_1 + t_2 + \dots + t_r - t_{r+1} \quad (t_i > 0)$$

2. M_{eff}

[illegible][illegible]

$\frac{1}{\sqrt{2}} \left(|0\rangle + i|1\rangle \right)$

Notes to Financial Statements
F 2022
(A RMB Y)

VIII. R

D , C : ,
(,). T
C :

T C ,
C . T C
C . T
, . T C
C
. T C S R M C
. T S R M C
,
C T C A C .

T C
 ,
 .

(I) C

C C

T C , , , .

T C -
 - . T C
 .

Notes to the Financial Statements

F 2022
(A RMB Y)

VIII. R ()

(I) C ()

T C ,
A
C . T C
F
C
T 2-9
S
C A B D P ' F
T C

(II) L

L
I C L
C B
12
A
C
V C
:

C B

| Item | 1st year | 1-2 years | 2-5 years | Over 5 years | Total |
|------|----------------|----------------|----------------|---------------|----------------|
| N | 997,944.00 | | | | 997,944.00 |
| B B | 211,396,818.18 | 223,154,176.00 | 153,052,040.00 | 69,285,680.00 | 656,888,714.18 |
| L - | 99,580,000.00 | 28,954,752.75 | 26,076,534.51 | | 154,611,287.26 |
| T | 311,974,762.18 | 252,108,928.75 | 179,128,574.51 | 69,285,680.00 | 812,497,945.44 |

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

VIII. Results of the Company's Operations (Continued)

(II) Profit and Loss Statement (Continued)

| I | Basic Earnings Per Share (RMB Yuan) | | | | Total |
|--------------------------|-------------------------------------|-----|-----|-------|----------------|
| | Weighted Average | 1-2 | 2-5 | Other | |
| Basic Earnings Per Share | 254,050,000.00 | | | | 254,050,000.00 |

Notes to Financial Statements
F 2022
(A RMB Y)

VIII. R ()

(III) M ()

Notes to Financial Statements
F 2022
(A RMB Y)

VIII. R ()

(III) M ()

3) O

O
T C
O 31 D 2022, RMB1,893,506
RMB1,893,506, 3%, 3%

IX. D

T
L 1
L 2
L 3
T

Notes to the Financial Statements
F 2022
(A RMB Y)

IX. D ()

(I) C f t t t f

| It | C f | | | t |
|-------|--------|--------|---------------|---------------|
| | M tL 1 | M tL 2 | M tL 3 | |
| I. C | | | | |
| ◆ F | | | 10,641,026.00 | 10,641,026.00 |
| 1. F | | | 10,641,026.00 | 10,641,026.00 |
| (1) | | | | |
| (2) I | | | 10,641,026.00 | 10,641,026.00 |
| (3) | | | | |
| 2. F | | | | |
| T | | | 10,641,026.00 | 10,641,026.00 |
| ◆ | | | 13,922,929.38 | 13,922,929.38 |
| 1. | | | 13,922,929.38 | 13,922,929.38 |
| (1) | | | | |
| (2) | | | | |
| (3) | | | 13,922,929.38 | 13,922,929.38 |
| 2. F | | | | |
| T | | | 13,922,929.38 | 13,922,929.38 |

(II) Q, t t , t t f t f t h , t t t f t t h f f 3 -

- Ma , Va Y a Va
a a .
- Ma a a a a a Va a a a
a Va a Y a Y
C a , Va : a ,
a , a , - a , a , a ,
a , . T Va a a
C a T Va a a a
C a , a a a
Va , N III, (XXXI) a .

N t t h F t t t

F 2022
(A RMB Y)

X. R

() If t f b t y


T. C. : G. W. , W. L. .

(.) If $t \in \mathcal{C}$ and $y \in \mathcal{C}$,

D C N VII. I .

(...) If $t \in \mathcal{C}$ and $t \in \mathcal{C}$ then $t \in \mathcal{C}$

F  C     ,  N VII. I

T  C

N f t t t t h h h C y

$$\text{C} \quad \text{H} \quad \text{K} \quad \text{H} \quad \text{C}, \text{L}.$$

A C

W A P C ., L

A C

C Y H C., L.

A C

H₂ Y H C₂L

A C

Notes to Financial Statements
F 2022
(A RMB Y)

X. R ()

(I) If the following items are:

| Notes to Financial Statements | Notes to Financial Statements | Notes to Financial Statements |
|-------------------------------|-------------------------------|-------------------------------|
| Y M H C | N - | C |
| N M B P A K | P | C |
| I M P | | |
| (L L P) | | |
| N F T Z S | | |
| I T C., L | | |
| S F H M | N - | C |
| C., L | | |
| W L | N - | C |
| Q K | N - | C |
| W H | D, , | |
| Z T E C | N - | C |
| C., L | | |

() If the following items are:

| | | | |
|---------------|---|--------------|--------------|
| 1. R | | | |
| S | / | | |
| | C | A, t f | A |
| | | | |
| Y M H C | M | 3,000,000.00 | 3,000,000.00 |
| C H K H C., L | | 71,199.48 | |
| W A P C., L | | 54,281.47 | 456,272.70 |
| J S H C., L | | | 2,372,524.98 |
| R | | | 682,184.79 |

Ninth Edition

F 2022
(A RMB Y)

X. R ()

() If t t tyt t (t)

2. $L \rightarrow L \rightarrow L$

T C  :

1. **Introduction**

Figure 1. The proposed model for the effect of the TiO_2 photocatalytic activity on the degradation of the organic pollutant. TiO_2 is irradiated by UV light, which produces electron-hole pairs. The electron-hole pairs react with the organic pollutant, which is degraded into CO_2 and H_2O .

N F T Z S I

| | | | | |
|---|--------|---|--|-----------|
| T | C., L. | P | | 24,380.95 |
|---|--------|---|--|-----------|

T C  :

A , t f b A

[illegible]

No. _____ h _____ t _____ t _____ R _____

 $Z \rightarrow T$

E\

C H 4

C., L.

| | |
|--------------|------------|
| 1,089,194.31 | 260,402.86 |
|--------------|------------|

Notes to Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

X. Related Party Transactions (Continued)

() If the transaction is not a financial transaction, it should be disclosed as follows:

3. Royalty Income

The following table shows the details of the royalty income:

| Contract Name | Contract Amount (RMB) | Contract Date | Contract Term | Contract Status |
|----------------------------------|-----------------------|---------------|---------------|-----------------|
| Yan Kangning Hospital Co., Ltd. | 50,200,000.00 | 2019/8/26 | 2029/8/20 | N |
| Qian Kangning Hospital Co., Ltd. | 45,000,000.00 | 2019/12/31 | 2024/12/31 | N |

The following table shows the details of the royalty income:

| Contract Name | Contract Amount (RMB) | Contract Date | Contract Term | Contract Status |
|--|-----------------------|---------------|---------------|-----------------|
| Gao Wengwei Medical Research Institute | 30,000,000.00 | 2020/6/30 | 2027/6/30 | N |
| Gao Wengwei Medical Research Institute | 75,000,000.00 | 2021/11/29 | 2028/11/29 | N |
| Gao Wengwei Medical Research Institute, Wenzhou Medical Research Institute | 150,000,000.00 | 2020/10/26 | 2026/10/25 | N |
| Gao Wengwei Medical Research Institute | 200,000,000.00 | 2020/9/17 | 2023/9/17 | N |

4. Asset Management

The following table shows the details of the asset management:

| Contract Name | Contract Amount (RMB) | Contract Date | Contract Term |
|------------------|-----------------------|---------------|---------------|
| Asset Management | | | |

Notes to the Financial Statements
F 2022
(A RMB Y)
X. R ()

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

X. Receivables ()

(II) Earnings before income tax

In 2022, the company's earnings before income tax were RMB 2,391,424.85.

| Name | Current year | | Previous year | | Other | |
|------------------------------------|--------------------------------------|------------------------|--------------------------------------|------------------------|--------------------------------------|------------------------|
| | Balance at the beginning of the year | Change during the year | Balance at the beginning of the year | Change during the year | Balance at the beginning of the year | Change during the year |
| Earnings before income tax | | | | | | |
| Government grants | | 413,976.00 | | 70,950.72 | 79,754.00 | 2,000.00 |
| Warranty income | | 516,000.00 | | | 96,000.00 | 71,000.00 |
| Warranty income | | 231,450.00 | | 50,888.16 | | 600.00 |
| Non-current assets impairment loss | | | | | | |
| Qinghai | | | | | | |
| Lianhua | | | | | | |
| Income tax | | | | | | |
| Zhang X | 70,000.00 | | | | | 70,000.00 |
| Zhang W | 70,000.00 | | | | | 70,000.00 |
| Lianhua | 70,000.00 | | | | | 70,000.00 |
| Income tax | | | | | | |
| Qinghai | | | | | | |
| Xin Y | | | | | | |
| Sun F | | | | | | |
| Xin N | | 313,320.00 | | 56,939.80 | 36,000.00 | 32,200.00 |
| Xin T | | 98,760.00 | | 40,146.72 | 67,954.00 | 3,485.45 |
| Total | 210,000.00 | 1,573,506.00 | 218,925.40 | 279,708.00 | 109,285.45 | 2,391,424.85 |

Other:

On September 1, 2022, the company's earnings before income tax were RMB 2,391,424.85. The company's earnings before income tax for the year ended December 31, 2022, were RMB 2,391,424.85.

2022 年度财务报表附注 (A 股上市公司财务报表附注)

2022

(A 股上市公司财务报表附注)

X. R ()

(II)E , t t f t (C t ,)

I 2021, , , , :

C

| <p> 2022 年度
 财务报表附注 </p> | E | <p> 2021 年度
 财务报表附注 </p> | <p> 2020 年度
 财务报表附注 </p> | <p> 2019 年度
 财务报表附注 </p> | <p> 2018 年度
 财务报表附注 </p> | <p> 2017 年度
 财务报表附注 </p> |
|--|------------|--|--|--|--|--|
| <p> 2022 年度
 财务报表附注 </p> | | | | | | |
| G W | - | 398,742.00 | 15,795.90 | 78,916.40 | 4,300.00 | 497,754.30 |
| W L | - | 375,592.00 | - | 46,714.60 | 44,680.00 | 466,986.60 |
| W H | - | 208,108.00 | - | 42,396.60 | 1,200.00 | 251,704.60 |
| <p> 2022 年度
 财务报表附注 </p> | | | | | | |
| L L | - | - | - | - | - | - |
| Y Y | - | 28,200.00 | 4,986.80 | 32,385.97 | 8,932.90 | 74,505.67 |
| <p> 2022 年度
 财务报表附注 </p> | | | | | | |
| Z X | 70,000.00 | - | - | - | - | 70,000.00 |
| Z W | 70,000.00 | - | - | - | - | 70,000.00 |
| L N | 70,000.00 | - | - | - | - | 70,000.00 |
| <p> 2022 年度
 财务报表附注 </p> | | | | | | |
| H J | - | - | - | - | - | - |
| Q C | - | - | - | - | - | - |
| C J | - | - | - | - | - | - |
| S F | - | - | - | - | - | - |
| X T | - | 82,613.40 | 8,885.40 | 54,030.60 | 18,936.60 | 164,466.00 |
| T | 210,000.00 | 1,093,255.40 | 29,668.10 | 254,444.17 | 78,049.50 | 1,665,417.17 |

Notes to the Financial Statements
F 2022
(A RMB Y)

X. R ()

(III) F I H t

I 2022, 2 (2021: 3),

| Item | Amount | Amount |
|----------------------|--------------|--------------|
| W | 3,764,039.10 | 3,424,382.50 |
| S | 4,109,519.26 | 4,411,564.18 |
| T | 7,873,558.36 | 7,835,946.68 |
| | | |
| | | |
| | | |
| 500,000-1,000,000.00 | 1 | 1 |
| Over 1,000,000.00 | 4 | 4 |
| T | 5 | 5 |

Notes to Financial Statements
F 2022
(A RMB Y)

XI. S -

(I) f h - y t

T C :

O J 13, 2018, C , 2018 W
K H E P 2018, B C
T B C P G R
S I O J 29, 2018 A 20, 2018, T C
, W Z K I
M P (L L P), W J K I M
P (L L P), W E K I M P
(L L P), W J K I M P (L
L P) W S K I M P (L
L P), 2,460,000

Notes to the Financial Statements

F 2022
(A RMB Y)

XI. S - ()

(II) E , ty- tt h - y t

M :
: 2022

T C :
: T :
C RMB30 .

M :
:

Notes to the Financial Statements
F 2022
(A RMB Y)

XII.C C

(I) f t t t

1. C 2 3 4

Notes to the Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

XIV. Government Grants

The Company has received government grants as follows:

— The Company received government grants for the purchase of scientific instruments and equipment, which are used for the research and development of new products, and are recorded as deferred income.

— The Company received government grants for the purchase of scientific instruments and equipment, which are used for the research and development of new products, and are recorded as deferred income.

The Company received government grants for the purchase of scientific instruments and equipment, which are used for the research and development of new products, and are recorded as deferred income. The Company also received government grants for the purchase of scientific instruments and equipment, which are used for the research and development of new products, and are recorded as deferred income.

The Company received government grants for the purchase of scientific instruments and equipment, which are used for the research and development of new products, and are recorded as deferred income.

All government grants are recorded as deferred income, and are amortized over the useful life of the related assets.

| D | / | B | B |
|--------|---|---|--------|
| | | | |
| 49.73% | | | 46.16% |

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

XV. Other non-current assets

(I) Other non-current assets

Receivables

As at December 31, 2022, the Company's receivables are primarily due from the government and various enterprises. The Company has provided a provision for doubtful debts based on the expected credit loss model. As at December 31, 2022, the Company's receivables are primarily due from the government and various enterprises. The Company has provided a provision for doubtful debts based on the expected credit loss model.

| Other non-current assets | Provision for doubtful debts | Net amount | Carrying amount |
|--------------------------|------------------------------|--------------|-----------------|
| Receivables | Provision for doubtful debts | Net amount | Carrying amount |
| 1,234,567.89 | 123,456.78 | 1,111,111.11 | -9,203,741.45 |
| | | | 12,877.91 |
| | | | 9,190,863.54 |

(II) Other non-current assets

As at December 31, 2022, the Company's other non-current assets are primarily due from the government and various enterprises. The Company has provided a provision for doubtful debts based on the expected credit loss model.

As at December 31, 2022, the Company's other non-current assets are primarily due from the government and various enterprises. The Company has provided a provision for doubtful debts based on the expected credit loss model.

(III) Other non-current assets

1. Other non-current assets

On December 14, 2023, the Company's other non-current assets are primarily due from the government and various enterprises. The Company has provided a provision for doubtful debts based on the expected credit loss model.

Notes to the Financial Statements

F 2022
(A RMB Y)

XV. O ()

(III) Ob f t , h h f , b f t (t ,)

1. I ()

(1) I RMB14.43

Ba S 2022, I
I A ,
2019 2020 RMB14.43 , RMB5.25
RMB9.18 , T
Ka H ,
I I C B D ,
(I) 2021, N XV

(2) R S W D C

A C
RMB2,190,700, C
C
T C
C
C

Net Profit Before Tax 2022 (A RMB Y)

XV. O  ()

(III) Ob f t , h h f , h f t (t , t)

1. I _____ ()

(3) R        

Barro and Sala-i-Martin (2003) find that the average growth rate of GDP per capita in the world is 1.8% per year, with a standard deviation of 1.5%. The average growth rate of GDP per capita in the world is 1.8% per year, with a standard deviation of 1.5%.

① P I C A

(2) A

C

, . ,

C

C

: B

C

T

Notes to the Financial Statements

F 2022
(A RMB Y)

XV. Other Intangible Assets

(III) Other Intangible Assets

2. A ()

(2) I 12 2019, 2020 2021
2020 2021
C
2020 2021, T
RMB428,900 2020 RMB335,100 2021,
C
2020 2021.

(3) O , C 2022

XVI. Non-current Assets Held for Sale

(I) A

1. A

| A | B | B |
|-----|---------------|---------------|
| | h | h |
| W 1 | 49,024,983.98 | 40,904,137.67 |
| 1-2 | 709,878.26 | 1,282,268.26 |
| 2-3 | 1,158,221.95 | 2,748,299.92 |
| O 3 | 2,748,299.92 | 1,204,242.08 |
| S | Over 3 years | 1,158,221.95 |

XVI. N

(I) $A, t \dots (t, \dots)$

2. A

[illegible]

Notes to the Financial Statements
F
(A 2022
(A RMB Y)

XVI. N ()

(I) A ()

2. A ()
A :

| Item | B () | | |
|-------|---------------|------------|-------|
| | A () | P () | P () |
| Other | 48,767,668.85 | 487,676.69 | 1.00 |
| Total | 48,767,668.85 | 487,676.69 | |

3. P ()
B ()

C ()

Notes to the Financial Statements
F 2022
(A RMB Y)

XVI. N ()

(II) Ob

| Item | Balance at the beginning of the period | Balance at the end of the period |
|--------------|--|----------------------------------|
| I | | |
| D | 53,000,000.00 | |
| O | 547,014,558.58 | 492,034,884.26 |
| T | 600,014,558.58 | 492,034,884.26 |
| 1. D | | |
| | Balance at the beginning of the period | Balance at the end of the period |
| | | |
| G K H C., L. | 33,000,000.00 | |
| Y K H C., L. | 10,000,000.00 | |
| Q K H C., L. | 10,000,000.00 | |
| S | 53,000,000.00 | |
| L : P | | |

North East
F 2022
(A RMB Y)

(

)

XVI, N

(II) Ob (t r)

Notes to the Financial Statements
F 2022
(A RMB Y)

XVI. N ()

(II) Ob ()

(3) P V

| P f t | t 1
12- b
ECL | t 2
L f t ECL
(N t
(t)) | t 3
L f t ECL
(C t-
(t)) | t |
|-------|---------------------|----------------------------------|-----------------------------------|------------|
| | | | | |
| B b b | 123,061.04 | | | 123,061.04 |
| B b b | | | | |
| / | | | | |
| -T 2 | | | | |
| -T 3 | | | | |
| -R 2 | | | | |
| -R 1 | | | | |
| P V | 103,420.62 | | | 103,420.62 |
| R V | | | | |
| W | | | | |
| W | | | | |
| O | | | | |
| B b b | 226,481.66 | | | 226,481.66 |

C V V :

| B | t 1
12- b
ECL | t 2
L f t ECL
(N t
(t)) | t 3
L f t ECL
(C t-
(t)) | t |
|-------|---------------------|----------------------------------|-----------------------------------|----------------|
| | | | | |
| B b b | 492,157,945.30 | | | 492,157,945.30 |
| B b b | | | | |
| / | | | | |
| -T 2 | | | | |
| -T 3 | | | | |
| -R 2 | | | | |
| -R 1 | | | | |
| A | 55,083,094.94 | | | 55,083,094.94 |
| D | | | | |
| O | | | | |
| B b b | 547,241,040.24 | | | 547,241,040.24 |

Notes to Financial Statements
 F
 (A 2022
 (A RMB Y)

XVI. N ()

(II) Ob ()

(4) P ,

| | B | C | R | W | B |
|-----|------------|------------|---|---|------------|
| C t | P | P | R | W | B |
| P | 123,061.04 | 103,420.62 | | | 226,481.66 |
| T | 123,061.04 | 103,420.62 | | | 226,481.66 |

(5) O

| | B | B |
|-----|----------------|----------------|
| N t | B | B |
| A | 507,207,052.64 | 481,560,443.31 |
| P | 33,132,118.55 | 8,954,970.91 |
| D | 5,933,350.00 | 854,300.00 |
| O | 968,519.05 | 788,231.08 |
| T | 547,241,040.24 | 492,157,945.30 |

附注五 合并现金流量表
F
(A 2022
(A 2022
RMB Y)

XVI. N ()

(III) L -t , ty t t

| It | B t b f b | | B b b P b | |
|---------|----------------|----------------|----------------|----------------|
| | B | t | B | b |
| I b | 649,079,592.72 | 649,079,592.72 | 613,070,215.90 | 613,070,215.90 |
| I b , b | 92,882,992.81 | 92,882,992.81 | 71,256,356.09 | 71,256,356.09 |
| b | 741,962,585.53 | 741,962,585.53 | 684,326,571.99 | 684,326,571.99 |

1. I b

| I t | B b b I b D b | | B t P b I b | |
|------------------------|----------------|---------------|----------------|----------------|
| | b | b | b | b |
| S Y M b I b C ,L . | 10,354,979.06 | | 10,354,979.06 | |
| Z b H b H b M b C ,L . | 34,627,432.36 | 34,627,432.36 | | |
| W K b J b F C | 500,000.00 | | 500,000.00 | |
| Z b K b H b M b C ,L . | 203,344,031.86 | 1,322,222.01 | 204,666,253.87 | |
| C b K b H b C ,L . | 51,982,515.15 | 715,222.35 | 52,697,737.50 | |
| Y K b H b C ,L . | 1,832,112.13 | 301,146.25 | 2,133,258.38 | |
| Y b K b H b C ,L . | 27,447,511.21 | 239,581.90 | 27,687,093.11 | |
| Q b K b H b C ,L . | 32,626,079.15 | 230,565.10 | 32,856,644.25 | |
| L b K b H b C ,L . | 2,110,854.98 | 188,216.41 | 2,299,071.39 | |
| W C H b C ,L . | 53,500,000.00 | | 53,500,000.00 | |
| W L Y H b C ,L . | 30,000,000.00 | | 30,000,000.00 | |
| W O b Y R b H b C ,L . | 10,000,000.00 | | 10,000,000.00 | |
| P b C b Y H b C ,L . | 154,744,700.00 | | 154,744,700.00 | |
| J b S H b C ,L . | | 26,684,900.00 | 26,684,900.00 | |
| Y Y b T b b | | | | |
| W M H b C ,L . | | 40,954,955.16 | 40,954,955.16 | |
| T b | 613,070,215.90 | 70,636,809.18 | 34,627,432.36 | 649,079,592.72 |

North F
F (A 2022 RMB Y)

()
()
B
I

()

O

C
A
I

(III) L
2. I

N D

I

XVI. N

Notes to the Financial Statements
附注
F
F
2022
(A
RMB Y)

XVI. Non-current Assets 非流动资产 (元)

(I) Long-term Receivables 长期应收款

1. Receivables from related parties 关联方应收款

| Item 项目 | Amount at the beginning of the year 年初余额 | Change 变动 | Amount at the end of the year 年末余额 |
|------------------------|--|----------------|------------------------------------|
| Medical equipment 医疗设备 | 337,586,514.02 | 264,978,847.50 | 365,462,139.23 |
| Others 其他 | 5,554,936.61 | 45,300.00 | 4,336,166.89 |
| Total 合计 | 343,141,450.63 | 265,024,147.50 | 369,798,306.12 |

Accounting policy 会计政策:

| Item 项目 | Amount at the beginning of the year 年初余额 | Amount at the end of the year 年末余额 |
|-------------------------|--|------------------------------------|
| Prepaid insurance 预付保险费 | 90,612,303.06 | 93,506,118.66 |
| Others 其他 | 246,974,210.96 | 271,956,020.57 |
| Total 合计 | 337,586,514.02 | 365,462,139.23 |

2. Receivables from other parties 非关联方应收款

Total 合计
The amount of receivables from related parties is RMB 369,798,306.12 at the end of the year, of which RMB 365,462,139.23 is due within one year, and RMB 4,336,166.89 is due after one year.

(II) Long-term Debt 长期借款

| Item 项目 | Amount at the beginning of the year 年初余额 | Amount at the end of the year 年末余额 |
|---------------------|--|------------------------------------|
| Long-term loan 长期借款 | 54,584,000.00 | 1,980,000.00 |
| Long-term loan 长期借款 | -5,377,605.11 | -3,485,811.81 |
| Long-term loan 长期借款 | -18,462.42 | |
| Long-term loan 长期借款 | 714,348.18 | 6,429,189.35 |
| Total 合计 | 49,902,280.65 | 4,923,377.54 |

Definitions

| | | |
|---------|--|--------|
| AGM | Annual General Meeting of the Company | C 2022 |
| A | Shareholder | C |
| A C | Shareholder | B |
| B Y H | B Y H C ., L . (北京怡寧醫院有限公司), PRC A 17, 2015, C | |
| B D B | B C | C |
| C K H | C K H C ., L . (蒼南康寧醫院有限公司), PRC J 15, 2012, C | |
| CG C | C G C A 14 H K L R | |
| C K P H | C K P H C ., L . (長春康林心理醫院有限公司), PRC F 16, 2016, C | |
| C K H | C K H H C ., L . (淳安康寧黃鋒醫院有限公司), PRC A 16, 2020, C | |
| C W K H | W K H C ., L ., PRC, H S M B H K S E (S C : 2120) | |
| C S | H K L R M . GUAN W M . WANG L | |

Definitions

| | |
|----------|---|
| CSRC | 中國證券監督管理委員會 |
| D () | 董事會 |
| D S () | 董事會秘書 ()
RMB1.00 元, RMB 元 S |
| G H | 溫州怡寧老年醫院有限公司, PRC N 2, 2015, C |
| G | C |
| G Y H | G Y H C ., L . (冠縣怡寧醫院有限公司), PRC M 1, 2017, C |
| HS () | 香港證券交易所有限公司, RMB1.00 元, M B |
| H C H | H C H C ., L . (杭州慈寧醫院有限公司), PRC N 18, 2017, C |
| H Y H | H Y H C ., L . (杭州怡寧醫院有限公司), PRC A 25, 2016, C
- O J 30, 2022, C
28% H Y H
T W L L H M C ., L . (桐鄉烏鎮蓮芯蓮意
健康管理有限公司). U
33% H Y H |
| H Y H | H Y P H C ., L . (荷澤怡寧精神病醫院有限公司), PRC A 6, 2017, C |
| HK\$ HKD | 香港 |

Definitions

H K

H K S A R

PRC

H K L R

Definitions

| | |
|--------------------------------------|---|
| Ningbo Yuhang Hospital | Ningbo Yuhang Hospital Co., Ltd. (南京怡寧醫院有限公司), a company incorporated in the PRC on July 22, 2018, with its registered office at Ningbo Yuhang Hospital, Ningbo, Zhejiang, PRC. |
| Ningbo Yuhang Hospital Co., Ltd. | Ningbo Yuhang Hospital Co., Ltd. (寧波怡寧醫院有限公司), a company incorporated in the PRC on July 22, 2018, with its registered office at Ningbo Yuhang Hospital, Ningbo, Zhejiang, PRC. |
| Ningbo Yuhang Hospital Co., Ltd. (A) | Ningbo Yuhang Hospital Co., Ltd. (寧波怡寧醫院有限公司), a company incorporated in the PRC on July 22, 2018, with its registered office at Ningbo Yuhang Hospital, Ningbo, Zhejiang, PRC. |
| Pudong Yuhang Hospital | Pudong Yuhang Hospital Co., Ltd. (浦江怡寧黃鋒醫院有限公司), a company incorporated in the PRC on September 3, 2018, with its registered office at Pudong Yuhang Hospital, Pudong, Shanghai, PRC. |
| PRC | People's Republic of China, including Hong Kong, Macao, and Taiwan. |
| PRC Company Law | Company Law of the PRC (中華人民共和國公司法), a law enacted by the National People's Congress on December 28, 2013, and amended on March 1, 2014. |
| P | Company Law of the PRC (中華人民共和國公司法), a law enacted by the National People's Congress on December 28, 2013, and amended on March 1, 2014. |
| Qingting Kangning Hospital | Qingting Kangning Hospital Co., Ltd. (青田康寧醫院有限公司), a company incorporated in the PRC on April 1, 2011, with its registered office at Qingting Kangning Hospital, Qingting, Zhejiang, PRC. |
| Qingting Yuhang Hospital | Qingting Yuhang Hospital Co., Ltd. (衢州怡寧醫院有限公司), a company incorporated in the PRC on November 20, 2015, with its registered office at Qingting Yuhang Hospital, Qingting, Zhejiang, PRC. |

Definitions

| | |
|--------------|--|
| T R P
R P | 31, 2022 |
| R C | B |
| RMB | PRC |
| SFO | (C 571 L H K), |
| S () | S () C RMB1.00 ,
D S () H S () |
| S () | () S () |
| S Y H | S Y H (深圳怡寧醫院, S Y
H C ., L . (深圳市怡寧醫院有限公司)), PRC
S 22, 2014, C -
H K L R |
| S R M C | B |
| | C O (C 622
H K) |
| | H K L R |
| S () | S C |
| S C | C S C PRC C
I |
| T K H | T K H C ., L . (台州康寧醫院有限公司),
PRC J 30, 2016, C -
H K L R |

Definitions

W N H W N P S H C ., L . (溫嶺南方精神疾病專科醫院有限公司), PRC J 20, 2018, C - T1 T -05.4175 -30538T (°)T 0.556 -0.

